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Abstract 
 
Uveal melanoma (UM) is the most common primary intraocular cancer of the eye in 
adults. Despite successful treatment of the primary tumour, approximately half of 
patients diagnosed with UM will develop metastases. To date, treatments for 
metastatic UM have had only limited effect, hence prognosis remains poor. Metastatic 
UM occurs predominantly in the liver. The mechanisms responsible for this remain 
largely unknown.  Investigations into the molecular and cellular processes underlying 
UM development and metastasis are essential to develop therapeutic approaches 
directed against dissemination of this disease. 
In vitro and in vivo models play a crucial role in basic and translational oncology 
research. The scope of the work presented in this thesis was to develop innovative 
and clinically relevant in vitro and in vivo preclinical models that reproduce various 
aspects of metastatic processes in UM. In Chapter 2, primary UM cells were used to 
establish 3D tumour spheroids which retained many morphological and molecular 
characteristics of the original tumour. These 3D tumour spheroids more accurately 
mimic the 3D in vivo environment in which cancer cells reside and as a result can be 
used in co-culture assays, drug assays, and further transferred to an animal model to 
examine metastatic progression. Chapter 3 outlined one such in vivo model; the chick 
embryo. This model represents an accessible and economical in vivo model that has 
long been used in developmental biology. A panel of UM cell lines that represent the 
characteristic genetic and morphological profile in UM were used to form tumour 
nodules on the chorioallantoic membrane (CAM) and metastatic colonisation in 
internal organs following intravenous injection. Cells predominantly homed to the 
chick embryo eye spreading widely within the uveal tract, and to the liver, 
representative of the disease in patients allowing for a better understanding in the 
spread of this disease. Furthermore, cell lines forming tumour nodules on the CAM 
can be further used to assess candidate therapeutic drugs in an in vivo setting.  
Chapter 4 aimed to investigate such drug candidates by assessing the effects of 
targeted clinical inhibitors on UM cell lines. One particular inhibitor, the bromodomain 
PPI inhibitor JQ1, caused cell cycle arrest in two UM cell lines paving the way for 
many further insightful investigations.  
The models established in this thesis represent valuable, inexpensive and rapid in 
vitro and in vivo systems that can improve our understanding of the metastatic 
process in UM and provide a platform for the preliminary testing of potential new 
agents to aid molecular-based cancer therapy. 
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General introduction 
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1.1 Uveal Melanoma 
 
Uveal melanoma (UM) is a rare and highly aggressive malignancy arising from 
melanocytes located in the uveal tract of the eye. The uveal tract comprises the iris, 
choroid and ciliary body (Figure 1). 
 
Figure 1.1. The uveal tract consists of the iris, choroid and ciliary body. 
1.2 Incidence and risk factors 
 
Although rare, UM is the most common primary intraocular tumour in adults [1]. It 
accounts for approximately 5% of all melanomas with an incidence of about 6 cases 
per million individuals per year in Europe [2]. UM is more common in Caucasians, 
occurring predominately in individuals with blue or grey eyes. Other risk factors 
include blonde or red hair and cutaneous freckles or nevi [3, 4]. UM incidence 
increases with age with the majority of cases diagnosed during the fifth decade of life 
[5]; only 1% of cases occur in younger patients under the age of 18 [6]. Males and 
females are affected equally [7]. Although there have been reports of familial UM, 
these are very rare comprising only 0.6% of all UM patients [8].     
1.3 Detection, diagnosis and treatment 
 
The majority of UM are detected by optometrists either during routine examinations 
or when a patient presents with symptoms.  The diagnosis of UM is based on clinical 
appearance of the tumour following ophthalmic examination with the slit lamp and 
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indirect ophthalmoscope including ultrasonography of the eye [9]. Where possible, 
treatment of the primary tumour aims to conserve the eye [10]. Eye sparing modalities 
include brachytherapy, proton beam radiotherapy (PBR), transpupillary 
thermotherapy, local resection and endoresection. In brachytherapy, a radioactive 
plaque, usually with Ruthenium 106 or Iodine-125 is used; the former is used more 
commonly in Europe whilst the latter is applied usually in the US.  
Treatment failure, resulting in secondary enucleation, is usually associated with a 
larger tumour size; however for smaller tumours local recurrences after brachytherapy 
are reduced to only 3% at 7 years [11]. PBR delivers a focused beam of heavy particle 
radiation to the region of tumour, enabling the treatment of different sizes and 
locations of UM tumours [11]. The local recurrence rate in PBR is similar to 
brachytherapy. Initially there was much interest in transpupillary thermotherapy as it 
is a minimally invasive procedure where an infrared laser disrupts the metabolic 
activity of the tumour cells by increasing the temperature for a brief time [12]. 
However, studies have demonstrated a higher rate of tumour recurrence of small 
choroidal melanoma after treatment with transpupillary thermotherapy, and thus 
where possible other methods are used when treating small choroidal melanomas 
[13]. The tumour can be removed surgically en bloc through a scleral opening i.e. 
local resection, or in a piecemeal fashion with a vitreous cutter passed through the 
retina i.e. endoresection. These can be performed in combination with some form of 
radiotherapy, following surgical resection [7]. 
 If the size or location of the tumour prevents eye sparing therapy, if there are 
complications with the conservative therapy, or if it is the patient’s choice, enucleation, 
(i.e. removal of the eye globe) is performed with subsequent insertion of a prosthesis 
[9]. 
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1.4 Prognosis 
 
1.4.1 Clinical and histopathological features 
 
Particular clinical and histopathological features in UM associated with a patients risk 
to develop metastasis have been identified [14]. Clinical features associated with a 
poor prognosis include large tumour size, ciliary body involvement and extraocular 
extension [15]. The histopathological features include the categorisation of UM cell 
type, the mitotic count, the presence/absence of closed connective tissue loops, as 
well as inflammatory cell infiltrates (i.e. macrophages and lymphocytes). With respect 
to cell morphology, UM are either spindle (cells are long and narrow with large nuclei 
and indistinct cytoplasmic borders), epithelioid (cells are polygonal with large 
pleomorphic nuclei), or mixed cell type. UM with epithelioid cells are associated with 
a poorer prognosis [16].  A high mitotic count, the presence of Periodic Acid Schiff 
positive closed loops and a large number of infiltrating macrophages [17] and 
lymphocytes [18] are also associated with a poor prognosis and increased risk of 
death from metastatic disease [15]. 
1.4.2 Genetic features  
 
1.4.2.1 Chromosomal aberrations 
 
UM is associated with non-random gross chromosomal alterations occurring on 
chromosomes 1, 3, 6 and 8.  Loss of one copy of chromosome 3 (monosomy 3) was 
first reported in 1996 by Prescher and colleagues to be the strongest predictor of 
metastatic spread and increased mortality [19]. Monosomy 3 is associated with a 
reduction in the 5-year survival probability from approximately 100% to less than 50% 
as a result of metastatic spread predominantly to the liver [15]. Loss of chromosome 
1p and chromosome 8 gains (polysomy 8q) are also significantly correlated with 
reduced survival [20]. Furthermore, analysis of chromosomal data from 602 UMs 
demonstrated that when occurring in isolation, monosomy 3 and polysomy 8q have 
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similar impact on survival, however in combination, they reduce the 5-year cumulative 
survival to 30% [21]. A recent study demonstrated the proto-oncogene C-MYC, 
located on 8q24.21, to be overexpressed in metastasising UM [22]. This is consistent 
with the overexpression of C-MYC in other cancer types thus highlighting its 
significance as a candidate gene for targeted therapy, discussed in more detail in 
Chapter 4.  
On the other hand, polysomy 6p, which is frequently found in tumours with disomy 3, 
has been associated with prolonged survival and thus referred to as having a 
“protective” effect [23]. Although this protective effect may be true in the majority of 
cases, it has also been observed in a small number of cases with monosomy 3 and 
additionally found together with polysomy 8q in disomy 3 tumours [24]. 
1.4.2.2 GNAQ/GNA11 
 
The most common oncogenic driving mutations in UM are activating mutations in the 
genes GNAQ and GNA11, the alpha subunits of the heterotrimeric GTP binding 
proteins. The mutations occur in a mutually exclusive manner and are found in 
approximately 86% of primary UM [25]. These mutations affect either the glutamine 
residue at the 209 position (Q209) or the arginine residue at the 183 position (R 183) 
in exons 4 and 5. Consequently, the genes remain locked in their active GTP bound 
state which in turn leads to the activation of downstream pathways including protein 
kinase C (PKC) and mitogen activated protein kinase (MAPK) signalling pathways. 
As a result, GNAQ and GNA11 have become potential therapeutic targets for the 
treatment of UM [26], discussed in more detail in Chapter 4. It is important to note that 
these activating mutations are also seen in uveal melanocytic naevi; believed to be 
early events in tumour development [27]. 
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1.4.2.3 BAP1 
 
Mutations in the BRCA1-associated protein 1 (BAP1) gene, located on 3p21, are 
associated with a high likelihood of metastasis in UM. Harbour and colleagues 
identified inactivating somatic mutations in BAP1 in ~ 85% of metastasising primary 
UM [28]. BAP1 is a deubiquitinating enzyme involved in several biological processes, 
including regulation of cell cycle and cell growth, chromatin dynamics and DNA 
damage response [29]. Studies have demonstrated an association between the 
presence of BAP1 mutations and loss of protein expression. Indeed, a lack of nuclear 
BAP1 protein expression has been associated with decreased survival time [30, 31]. 
Knock down of BAP1 by RNAi has also been found to trigger a loss of cell identity 
characterised by the emergence of stem-cell like characteristics in UM cells [32]. 
Germline mutations in BAP1 have also been reported, although a low frequency, and 
are associated with a predisposition of individuals with this mutation to a variety of 
cancers including UM, lung adenocarcinoma and meningioma [33]. BAP1 plays a key 
role in UM metastasis, as a result studies have aimed to identify therapeutic agents 
that reverse the phenotypic effects of BAP1 loss. This led to the identification of 
histone de-acetylase inhibitors (HDACi), where UM cells treated with these agents 
showed reduced growth and a differentiated state in vitro and in vivo [34]. 
1.4.2.4 SF3B1 
 
Splicing factor 3B subunit 1 (SF3B1) mutations at arginine-625 were identified in 
primary UM patient samples by exome sequencing. These mutations are associated 
with favourable prognostic features such as fewer epithelioid cells, younger age, and 
inversely associated with poor prognostic features such as monosomy 3 and BAP1 
mutations [35]. However, metastasis may still occur in patients with tumours that 
harbour SF3B1 mutations and retain BAP1 expression [36]. SF3B1 encodes a 
component of the spliceosome, mutations in this component have been reported to 
alter gene splicing and in UM are associated with alternative splicing of the 3′ end of 
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mRNA transcripts [37]. Further investigations are required to understand the 
functional significance of this alternative splicing and the prognostic significance of 
SF3B1 mutations. 
1.4.2.5 EIF1AX 
 
The eukaryotic translation initiation factor 1A, X-linked (EIF1AX) gene has also been 
found to be mutated in UM and similar to SF3B1 mutations is associated with a better 
prognosis [38]. Martin and colleagues identified the EIF1AX mutation in 3 primary UM 
that were disomy 3 and lacked SF3B1 mutation [39]. 
1.5 UM Metastasis 
 
Despite the advances in the treatment of primary UM, almost 50% of all patients 
develop metastatic disease [2]. Due to the lack of a lymphatic system in the eye, UM 
dissemination occurs via the blood stream with the highest tendency of metastasis, 
up to 90%, in the liver. Less common sites of metastasis include the lungs, bone and 
skin. The prognosis for liver metastasis is very poor, with a median survival of 
approximately 8 months [40]. Systemic treatment options, such as intravenous 
chemotherapy and immunotherapy do not seem to give promising results for survival 
in patients with UM metastasis [41]. Emerging treatments for metastatic UM has 
aimed to target molecular drivers in UM including the MEK/MAPK pathway, discussed 
in more detail in Chapter 4. However, although improvement in progression free 
survival with MEK inhibitor treatment have been reported, these results need to be 
taken with caution given the small number of patients in the trial [42]. In selected 
patients, surgical resection of liver metastases can be beneficial, however this will 
only prolong survival. 
Clinically evident metastasis may occur several years, even decades [43] after 
treatment of the primary tumour and this has led to speculation about the timing of the 
haematogenous spread from the eye and also the possibility of tumour dormancy at 
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distant sites. Since tumour cells can remain dormant, metastasis may occur long 
before the primary tumour is of a detectable size and as a result patients may already 
have micrometastatic UM [40]. Clinically evident metastasis at the time of primary 
tumour diagnosis is infrequent, found in only 1–2% of cases [44].  
To better understand metastatic UM, Grossniklaus evaluated the histological sections 
of livers obtained at autopsy from patients who died of metastatic UM. He categorised 
these into 3 stages based on size; avascular stage 1 metastases that progress to 
stage 2, to larger stage 3 tumours that become vascularised as they progress and 
enlarge [45]. It is still unclear how and when this progression occurs. Furthermore, 
the majority of UM cells in the liver present with ‘miliary’ disease (multiple, diffuse, 
millimetre-sized tumour cells), as a result treatment of UM metastasis has to date 
proved difficult [9].  
1.6 Models of UM 
 
Since little is known about the characteristics of UM cells that metastasise and grow 
in the liver, it is essential that the metastatic process is better understood. 
Experimental models of UM that are able to faithfully replicate aspects of tumour 
development and metastasis are therefore essential to facilitate this. In the past, the 
majority of in vitro models have focused on two-dimensional (2D) cultures using 
established cell lines, however more recently there has been increasing interest in 3-
dimensional (3D) cultures. Traditional 2D environment does not allow for areas of 
hypoxia, heterogeneous cell populations, varying cell proliferation zones or 
extracellular matrix influences, and as a result may not accurately mimic the 3D in 
vivo environment in which cancer cells reside. However 3D culture systems exhibit 
features that are closer to the complex in vivo conditions, hence prove a more 
valuable model with which to study tumour cells and potential chemotherapeutics, 
discussed in more detail in Chapter 2.  
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Animal models also play a vital role in providing further insight into the behaviour of 
the disease in a more representative microenvironment. Many attempts have been 
made to develop a suitable animal model to study UM, and to induce intraocular 
melanoma. Generally, these models are divided into spontaneous, transgenic and 
induced models. Spontaneous tumours and their metastasis occur naturally, and have 
been reported in certain animals including, mice, rats, cats, dogs, horses, birds and 
fish [46]. However, their use as a model in UM is limiting since these tumours are very 
rare, occur randomly and in an unpredictable manner.  
Transgenic models in which key genes are knocked out or knocked in to induce 
tumour growth, offer the opportunity to study the earlier stages of malignancies. The 
majority of transgenic UM models have been developed in mice where tumours either 
grow from retinal pigment epithelium (RPE) or are mixed tumours of RPE and UM. An 
exception to this is the TollTyr-RAS+ Ink4a/Arf-/- transgenic mice, which do not 
contain RPE cells [47]. Unfortunately metastasis has not been reported in any of these 
models, and only occur when tumour cells are cultured and then transferred [48]. 
Recently, Schiffner and colleagues used the Tg (Grm1) transgenic mice, known to 
spontaneously develop highly pigmented nodular melanomas in hairless skin regions, 
to demonstrate development of choroidal thickening with a ciliary body tumour [49]. 
However further studies are required to demonstrate whether these cells have the 
capacity to metastasise or not.  
In induced animal models, tumour development occurs following exposure to 
chemical agents, radiation, virus or when tumour cells and tissues are xenografted 
into the animal [50]. These models are easier to use as the experiments can be 
repeated yielding similar results.  
One cell line commonly used for this purpose is the Greene melanoma cell line, a 
spontaneous cutaneous melanotic melanoma discovered in Syrian golden hamsters, 
which developed into an amelanotic melanoma after continuous passage [51]. In one 
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study, the Greene melanoma cell line was implanted subcutaneously to investigate 
the effect of hyperthermia on developing tumours. The results of this study led to the 
use of transpupillary thermotherapy in the treatment of UM patients [52-54]. A further 
cell line, the Bomirski cutaneous melanoma, identified in a male Syrian golden 
hamster that had developed a black skin tumour [55], has also been used in ocular 
melanoma research. Small fragments of melanoma tissues were implanted into the 
anterior chamber of hamsters to investigate radio sensitivity, and tumour 
vascularisation [56, 57]. Although these cell lines have been reported to metastasise 
in the hamster model, as summarised in Table 1.1, they are not of ocular origin and 
therefore not representative of ocular tumours. Furthermore, the small size of the 
hamster eye limits its practicality as a model. 
Table 1.1 Hamster model 
Cell line Inoculation site Metastasis Reference 
Greene Subcutis 
Vein and artery 
Liver 
Lung, liver, kidney, thymus, heart 
[51, 58] 
Greene Subcutis None reported [52, 53] 
Greene Subcutis None reported [54, 59] 
Bomirski Subcutis Lung, kidney, lymph node [55] 
Bomirski Anterior Chamber Lymph node [56] 
Bomirski Anterior Chamber Lung, kidney [57] 
 
Attempts to establish UM cell lines from rats have not been successful and as a result, 
cell lines from other species have been used in the rat model. Braun and colleagues 
used the athymic albino WAG/RijHs-rnu rat to implant human UM cells (Table 1.2) 
either by placing tissue or minced tissue into the choroidal space or by injecting 
tumour spheroids in the suprachoroidal space [60, 61]. The majority of the animals 
injected with the spheroids developed intraocular tumours. However no metastasis 
was reported in any of the investigations hence limiting this model to studying primary 
intraocular tumours only. 
 
20 
 
Table 1.2 Rat model  
Cell line Inoculation site Metastasis Reference 
OCM-1, C918, M619 Suprachoroidal None reported [60-63] 
 
Unlike the hamster and the rat, rabbits have larger eyes allowing for much easier 
access and examination. The different cell lines used in this model include the B16F10 
cell line of murine cutaneous origin, the Greene melanoma cell line and the human 
UM cell lines (Table 1.3). The well-characterised B16F10 cell line has been placed in 
the subchoroidal space of the rabbit eye in many studies, however not only does this 
cell line require the injection of cyclosporin A (CsA) which reduces the immunity and 
life span of the rabbits, it is also of cutaneous origin. The Greene melanoma cell line 
on the other hand does not require immunosuppression in the rabbit [46] and has 
been placed into the anterior chamber (AC) or subchoroidal space of the rabbit eye 
to develop ocular tumours and to investigate treatments [64]. Both the B16F10 and 
Greene melanoma cell lines have failed to show metastasis to the liver in this model 
(Table 1.3). Human UM cell lines have been successfully implanted in the rabbit eye 
and have shown metastatic spread to distant organs (Table 1.3) [44]. Blanco and 
colleagues injected the human UM 92.1 cell line into the suprachoroidal space of 
rabbit eyes; all the animals developed metastasis to the lungs and 18% developed 
micrometastasis to the liver [65].  
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Table 1.3 Rabbit model 
Cell line Inoculation site Metastasis Reference 
B16F10 Subchoroidal None reported [66-68] 
B16F10, OCM1 Subchoroidal None reported [69] 
OCM1 Suprachoroidal None reported [70] 
MKT-BR Suprachoroidal Lung [71] 
IPC227 Anterior chamber None reported [72] 
MKT-BR, OCM1, 
92.1, SP6.5 
Suprachoroidal Lung [73] 
92.1 Suprachoroidal Lung, liver [65] 
92.1 Suprachoroidal Lung, liver [74, 75] 
92.1 Suprachoroidal None reported [76] 
92,1 Suprachoroidal None reported [77] 
Greene Subchoroidal Kidney [78] 
Greene Suprachoroidal None reported [64] 
Greene Anterior chamber None reported [79] 
Greene Anterior chamber None reported [80] 
 
Due to the similarity of the mouse genome to human genome, mice are widely used 
in cancer research [50]. The B16F10 and the Queens melanoma cell line, a subculture 
of the B16F10 cell line, have both been successfully transplanted in the AC of the 
mouse eye as summarised in Table 1.4, resulting in tumour development. Metastatic 
spread in the liver, however, was not observed in any of the studies. A derivative cell 
line of B16 cell line, B16LS9 cell line, has been shown to metastasise to the liver when 
injected in the posterior chamber (PC) [81]. Dithmar and colleagues demonstrated 
that transcorneal inoculation of these cells into the murine PC leads to 
haematogenous metastases to the lung and liver [46]. This model has further been 
used in several studies to investigate tumour angiogenesis and tumour biology, 
summarised in Table 1.4.  
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Table 1.4 Mouse model 
Cell line Inoculation site Metastasis Reference 
B16F10 Anterior chamber Lung [82] 
B16F10 Anterior chamber None reported [83] 
B16F10, Queens Anterior chamber None reported [84] 
B16F10, Queens Posterior chamber Lung 
B16F10 Anterior chamber None reported [85] 
B16F10 Anterior chamber None reported [86] 
B16LS9 Posterior chamber Lung, liver [87] 
B16LS9 Posterior chamber Lung, liver, lymph 
node 
[46] 
B16LS9 Posterior chamber Liver [88] 
B16LS9 Posterior chamber None reported [89] 
B16LS9 Posterior chamber, 
spleen  
Liver [90] 
B16LS9 Posterior chamber, 
spleen 
Liver [91] 
OCM1, OCM3, OCM8, EOM3, 
92.1, OM431, MEL202 
Anterior chamber Liver [92-94] 
C918, MUM2B Subcutis None reported [95] 
OCM1, MUM2B Subcutis None reported [96] 
OMM1.3 Retro-orbital Lung, liver [97] 
 
Human xenografts with human cell lines and human tumour fragments are now more 
widely used in research to investigate metastasis and treatment strategies. Orthotopic 
and ectopic xenografts have been established where human UM cell lines are placed 
subcutaneously in the flanks of athymic mice [95, 96]. Similarly, Heegaard and 
colleagues implanted UM specimens subcutaneously into the flanks of nude mice, in 
order to establish a serially transplantable tumour model, however the take rate of the 
transplantable tumour was very low (13%) [98]. Furthermore, metastasis was not 
reported in any of these studies (Table 1.4). However, Surriga and colleagues 
transplanted EGFP labelled UM cells by retro-orbital injections and reported 
metastasis to lung and liver of the mice 6-7 week after injection [97]. Other studies 
have placed xenografts derived from primary human UM or from UM metastasis in 
the interscapular fat pad of immunodeficient mice; these tumours show the original 
human gene expression profiles and mutations, and have allowed for the 
evaluation of drug candidates and for predicting therapeutic efficacy by screening 
molecular markers [99, 100]. Nemati and colleagues established a panel of 
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primary human UM xenografts obtained from patient tumour samples 
transplanted into severe combined immunodefficient (SCID) mice [101]. These 
patient derived xenografts (PDX) showed complete concordance with the patient 
material with regard to the GNA11, GNAQ, BAP1 and SF3B1 mutations. Recently, 
Amirouchene-Angelozzi and colleagues established a panel of 7 UM cell lines 
from either patient’s tumours or PDXs. All the cell lines displayed GNAQ or 
GNA11 mutations, with four of these displaying BAP1 deficiency [102]. However, 
the relative tumour take in these models is rather low and liver metastasis have 
not been reported. In many studies, although tumour growth is reported, tumour 
metastasis has proved more difficult to achieve. As a result some of these models 
can only be used to study the primary tumour. However, each model has its own 
relevance; PDX models are used to generate tumours that are representative of 
the tumour of origin and not always employed as a spontaneous metastasis 
model. On the other hand, orthotopic models have been used to study both the 
tumour in its natural environment and to examine the possibility of spontaneous 
metastasis. Therefore, collectively each model can address the different 
questions surrounding tumour biology and tumour metastasis.    
Until recently the current available cell lines did not completely reflect the genetic 
alterations found in UM, for example, many of the models use cell lines derived 
from cutaneous melanoma that are biologically and genetically different to UM 
(i.e. they harbour BRAF mutations) [103]. Furthermore, models have failed to 
recapitulate the metastatic processes that occur in UM, as many do not show any 
metastasis to key organs such as the liver. It is unclear why so few tumours give 
rise to xenografts and why many fail to induce liver metastasis. In an effort to use 
well established representative UM cell lines in a cost effective model and to 
investigate the effect of inhibitors, van der Ent and colleagues used the zebra fish 
and injected fluorescently labelled UM cell lines into the yolk sac of the embryos 
24 
 
[104]. However, as a model, zebrafish lack some of the mammalian organs, such 
as lung and mammary gland. In order to be able to study the mechanism of UM 
metastasis and assess drug therapeutics, we still require suitable animal models 
which are cost effective, do not require immunosuppression, easily accessible / 
visualised, and efficient in terms of achieving results in a short period of time. One 
such model, the chick embryo model has previously been used in a small number 
of studies in UM, however as discussed in more detail in Chapter 3 these have 
failed to either use representative cell lines or to demonstrate liver metastasis.  
UM is a complex and diverse disease, this thesis has set out to investigate and 
provide baseline platforms, from 3D in vitro environments to in vivo setting of an 
animal model with which to better understand UM and the mechanisms involved 
in the metastasis, and finally to establish therapeutic targets for the treatment of 
this disease.  
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Chapter 2 
Formation and characterisation of UM spheroids in a 
3D in vitro model 
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2.1 Introduction 
 
The introduction of mammalian cells in in vitro culturing systems has led to many 
advances in cell biology and the understanding of formation and function of tissues, 
as well as disease states such as cancer. The majority of these discoveries have been 
through the traditional two-dimensional (2D) culture techniques. However, 2D culture 
systems can inadequately reﬂect the biological features of original tumours and their 
environments; for example, in 2D culture cell-to-plastic interactions prevail rather than 
the crucial cell-to-cell and cell-to-extracellular matrix (ECM) interactions, which are 
the basis of normal cell function. Thus, alternative culture systems of cancer cells that 
realistically reﬂect the characteristics of parental tumours have been established to 
study cancer biology. Three-dimensional (3D) culture systems have become a 
popular method to recapitulate the in vivo-like growth and differentiation of tissues as 
compared to 2D-models. The most widely used 3D model system at present is the 3D 
tumour spheroid assay, which preserves the characteristics of the original tumour and 
has further shown correlation with the in vivo situation when testing the effects of 
anticancer agents [105].  Spheroids have been produced from either a single cell type 
or as complex multicellular spheroids, reflecting the in vivo cells found in the tumour 
of interest. Multicellular tumour spheroids resemble avascular tumour nodules or 
micrometastases with respect to growth kinetics and some histomorphological 
features [106]. With increasing size of either the mono- or multi-cellular spheroids, 
proliferation and oxygen/nutrient gradients are observed, features that affect not only 
cellular RNA and protein expression but also the penetration and bioactivity of drugs 
[106].  
As highlighted in Chapter 1, there are currently no effective treatment options once 
UM has disseminated. Our knowledge about the processes involved in UM metastasis 
is limited, and there are currently no well-characterised in vitro models with which to 
investigate these processes or perform preclinical drug testing. As a result, 
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developing a 3D model system that can be used to explore the biology of UM and 
assess therapeutic drugs preclinically, can pave the way in discovering better 
treatment options for metastatic UM.  
Sutherland and colleagues were the first to describe the use of 3D spheroids in cancer 
research [107]. By utilising the spinner culture method, they cultured Chinese hamster 
lung cells as spheroids and described an outer zone containing many proliferating 
cells, an intermediate zone that is poorly nourished and oxygenated and contains few 
cells in mitosis, and a central zone of necrosis. They further dissociated the spheroids 
and used the single cells for colony formation and highlighted the use of this model 
for assessment of the effects of nutrition and oxygenation on growth and for 
determination of the cell growth fraction after treatment with drugs or radiation [107]. 
The spinner culture method creates mass spheroid culture by preventing cells in 
suspension from settling and by stimulating cell-to-cell collision via constant stirring. 
Using this method, culture conditions, such as changes in medium and addition of 
growth factors or drugs, can be easily carried out [108]. Firth and colleagues showed 
fundamental differences between the cells cultured in monolayer and in spinner 
flasks; they reported altered immunophenotypes, including loss of human leukocyte 
antigen (HLA) class I molecules, and enhanced osteogenic and adipogenic 
differentiation in mesenchymal stem cells (MSCs) cultured using the 3D techniques 
when compared with 2D monolayers [109]. Following Sutherlands work, several other 
methods have been developed to generate tumour spheroids including; micro-
moulded non adhesive hydrogels, scaffolds, liquid overlay, and hanging drops.  
Micro-moulded non-adhesive hydrogels have been used to form spheroids with 
different shapes. Micro-moulds are created using computer-aided design software 
from which non-adhesive hydrogels are cast. Cells settle and form spheroids at the 
bottom of each recess created. In a single mould, a large number of spheroids with 
homogenous size, shape and cellular compositions can be created. Desroches and 
28 
 
colleagues used this technique with 822 moulds creating cardiac myocyte (CM) and 
cardiac fibroblast (CF) spheroids. Neonatal rat ventricular CMs and CFs, alone or in 
combination, self-assembled into viable spherical-shaped microtissues. Furthermore, 
when seeded simultaneously or sequentially, CMs and CFs self-sorted were 
interspersed, creating cellular structures reminiscent of their in vivo myocardial 
distribution [110].  
The liquid overlay method prevents cells from adhering to the culture plates and 
therefore encourages cell-cell aggregation. Tissue culture flasks or dishes are coated 
with agarose or poly-2-hydroxyethyl methacrylate (polyHema) and allowed to dry 
[111]. In an early study, liver cells isolated from new-born rats cultured in polyHema 
coated Petri dishes were found to spontaneously form aggregates and within a few 
days form spheroids. Furthermore, after further analysis by immunohistochemistry 
(IHC), cell types such as hepatocytes that regrouped in small islands often defining a 
central lumen, and cells that reorganised into bile duct-like structures were reported 
[112]. This method is simple, widely-utilised to date, and is also cost effective.  
In the hanging drop method, small volumes of cell suspensions are placed on the 
inside of a Petri dish lid and inverted. This method relies on gravitational force as the 
droplets stay attached to the lid via surface tension and cells settle at the bottom of 
the drop, resulting in the formation of a single spheroid. Kelm and colleagues used 
this method to generate tumour spheroids from hepatoma and adenocarcinoma cell 
lines, which revealed highly organised, three-dimensional, tissue-like structures with 
an extensive extracellular matrix [113]. Spheroid size in this technique can be 
controlled by altering the cell density in the drop, and high throughput methods have 
been developed producing up to 384 spheroids in a single assay [114].  
More recently, however, studies have used the ultra-low attachment (ULA) 96-well 
round bottom plates that, in comparison to the other standard methods, do not require 
pre-coating to prevent cell adhesion. In addition, the well shape promotes the 
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formation of single, centrally located spheroids of reproducible size [106]. Vinci and 
colleagues used this method to test 40 cell lines and classified each according to their 
morphology; tight spheroid, compact aggregate and loose aggregate. They further 
evaluated the sensitivity of the tumour spheroids in 2D and 3D cultures to three 
specific molecularly-targeted agents. Tumour cells were found to be generally less 
sensitive to compounds in 3D culture than in 2D culture, highlighting the importance 
of accurately evaluating drug responses under appropriate conditions in vitro in order 
to avoid overestimating or underestimating the effect of compounds prior to in vivo 
studies [106]. This high throughput and reproducible method of tumour spheroid 
formation allows for simple and time efficient analysis from imaging, comparing, 
treating, characterising and collecting the 3D tumour spheroids to further enhance our 
understanding of in vivo processes. 
The focus of this chapter was to assess the ability of UM cell lines and primary UM 
cells to form tumour spheroids and to reproduce aspects of the in vivo tumour and its 
microenvironment.
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2.2 Materials and Methods 
2.2.1 Cell culture 
 
For routine cell line culture, UM cell lines (Table 2.1) were maintained in UM medium 
A; RPMI (PAA Laboratories, Somerset, UK) supplemented with 10% fetal calf serum 
(FCS; PAA Laboratories), 2 mM l-glutamine (Sigma, Dorset, UK), and antibiotics 
(penicillin 50 IU/ml, streptomycin 500 µg/ml) [115]. They were incubated under 
standard conditions (37°C, 5% CO2, 95% humidity). For all studies, UM cell lines 
(~70% confluent) were harvested with 0.05% trypsin/EDTA (Life Technologies, 
Paisley, UK) and re-suspended in appropriate medium at varying cell density as 
indicated below. The primary human UM cell line MEL270 and the cell lines OMM2.5 
and OMM2.3 derived from a liver metastasis of the same patient  [116], the primary 
UM cell line 92.1 [80] and the subcutaneous metastasis cell line OMM1 were all kindly 
provided by Martine Jager (Leiden University, Leiden, The Netherlands).  The patient-
derived tumour xenograft (PDX) cell line, MM66, established from a liver metastasis 
[102], was kindly provided by Sergio Roman-Roman (Institut Curie, Paris) (Table 2.1).  
Following approvals from the local and national ethics committees (NRES reference: 
15/SS/0097), fresh UM specimens were acquired via the Liverpool Ocular Oncology 
Biobank (LOOB) from patients undergoing enucleation or local resection. For primary 
cell culture, a small sample of fresh UM tissue from an enucleation or local resection 
was finely minced with a sterile scalpel blade. It was then digested with 5 ml of type I 
collagenase (Sigma) at 37°C for approximately 40 minutes. To assess the presence 
of single cells, 10 μl of the suspension was placed onto the haemocytometer and 
observed under a microscope. The debris was then allowed to settle and the 
supernatant containing the single cells transferred to a new tube and centrifuged at 
1800 rpm for 2 minutes. The cell pellet was resuspended in primary cell culture 
medium, UM medium B; α-MEM (Sigma), AmnioSelect (Metachem Diagnostics LTD), 
FCS (Labtech), 2 mM l-glutamine (Sigma, Dorset, UK) and antibiotics 
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(penicillin 50 IU/ml, streptomycin 500 µg/ml). A minimum of 1 million cells were plated 
in T75 flasks and placed in an incubator until cells reached ~80% confluence. Primary 
cells were pre-cultured to ensure sufficient number of cell for the assays to be carried 
out, as not all primary samples successfully survive in culture.  
Table 2.1 UM cell lines characteristics 
Wt = wild type, G = gain, N = normal 
2.2.2 Cell suspension assay 
 
PolyHema solution was prepared at 12 mg/ml in 95% ethanol, the solution was stirred 
overnight at 37 °C. 6 cm Petri dishes were coated with 300 µl of polyHema solution 
and allowed to dry overnight. The UM cell lines 92.1, MEL270, OMM2.3 and OMM1 
were plated at 30,000 cells in the polyHema coated Petri dishes in 6 ml of UM medium 
A. Following 10 days of incubation, images were taken on an inverted light 
microscope. 
2.2.3 Hanging drop assay 
 
The UM cell lines 92.1, OMM2.3, OMM2.5 and OMM1 were harvested as described 
in 2.2.1 and plated as individual droplets of 7,500 cells on an inverted 6 cm Petri dish 
lid with a pipette. The Petri dish lid was then carefully inverted on to the dish containing 
PBS to prevent the cell suspension droplets drying. Images of the individual droplets 
were taken on an inverted microscope at 4x magnification, after 2 and 4 days of 
incubation respectively.  
2.2.4 ULA 96-well plate spheroid assay 
 
 Cell line 
92.1 MEL270 OMM2.3 OMM2.5 OMM1 
Origin Primary Primary Liver 
metastasis 
Liver 
metastasis 
Subcutaneous 
metastasis 
BAP1 wt wt wt wt wt 
GNAQ/GNA11 GNAQ Q209 GNAQ Q209 GNAQ Q209 GNAQ 
Q209 
GNA11 Q209 
Chromosome 3 Partial 
deletions 
wt wt wt wt 
Chromosome 8 G N N N G 
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UM cell lines 92.1, OMM2.3 and OMM2.5 and primary cells,  were harvested as 
described in 2.2.1, 100 µl/well of cell suspensions were dispensed into the ULA 96-
well-round-bottom plates (Appleton Woods LTD, Birmingham, UK) using a 
multichannel pipette. The cells were plated at varying cell densities indicated below 
to assess their ability to form tumour spheroids. They were imaged after 7 days of 
incubation using an inverted microscope, at 4x magnification.  Further spheroid 
assays with primary cell lines were carried out similarly with cells plated at densities 
indicated and imaged on the Axio ObserverZ1 Zeiss Microscope. Spheroid 
measurements were taken by measuring the diameter of each tumour spheroid 
horizontally and vertically since not all spheroids were completely spherical in shape 
(Figure 2.1).  
At days 3, 6 and 9 of incubation, measurements and images of each spheroid was 
taken, and two spheroids from each cell density were removed and fixed in 10% 
neutral buffered formalin overnight,  and were then placed in molten agar to set. The 
formalin-fixed spheroids were then placed in tissue cassettes before being loaded 
onto the BAYER VIP E300 tissue processor. The spheroids underwent dehydration 
in a series of alcohol and xylene incubations before being finally maintained in hot 
wax ready for embedding. Spheroids were then embedded in paraffin by carefully 
orienting them in the wax to set in the centre of the block. 
 
 
 
 
 
Figure 2.1. Representative images of UM tumour spheroids showing measurements of the 
diameter in the different shapes. 
 
200 µm 200 µm 
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2.2.5 Histological assessment and immunohistochemistry (IHC) 
 
Sections (4µm) were cut from paraffin-wax-embedded spheroid samples, and floated 
onto X-tra® adhesive slides (Leica, Milton Keynes, UK), which have a positive 
charged surface to help bond tissue sections onto the glass. For histological analysis, 
sections were stained with Haematoxylin and Eosin (H&E): slides were first 
deparaffinised in xylene, and rehydrated to water through a series of decreasing 
ethanol concentrations. Following immersion in haematoxylin, the slides were 
incubated in tap water to allow the stain to develop; and then acid alcohol to destain. 
They were then stained with eosin and dehydrated through ethanol before 
coverslipping with using DPX mountant (Sigma, Dorset, UK). 
IHC assays were undertaken using the FLEX Envision kit (DAKO) as follows. Applying 
a PT Link (DAKO, Ely, UK) pre-treatment module, high-pH (Tris/EDTA buffer, pH 9.0) 
antigen retrieval was performed at 96°C for 20 minutes. The slides were then washed 
in FLEX wash buffer (Tris-buffered saline solution containing Tween 20, pH 7.6) prior 
to loading onto the automated DAKO autostainer system. Using the FLEX Envision 
system (DAKO) according to the manufacturer’s instructions, IHC was performed as 
follows; (1) blocking of endogenous peroxidase (phosphate buffer containing 
hydrogen peroxide, 15 mmol/L NaN3 and detergent) for 5 minutes at room 
temperature (RT); (2) incubation with primary antibodies or isotype controls as 
appropriate (Table 2.2) for 30 minutes at RT; (3) incubation with mouse linker for 15 
minutes at RT; and, (4) incubation with horseradish peroxidase for 20 minutes at RT. 
Positive staining was visualised with 3-amino-9-ethylcarbazole (AEC, Vector 
Laboratories Ltd., Peterborough, UK, 30min) or 3,3'-Diaminobenzidine (DAB, DAKO, 
Ely, UK, 10min). Slides were washed between each incubation with 1× FLEX wash 
buffer. 
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Counterstaining was performed with Mayer’s haematoxylin (VWR, Leicestershire, UK) 
and slides were mounted with either Aquatex aqueous mounting medium (Merck 
Millipore, Nottingham, UK) for slides using the AEC detection system or dehydrated 
through a series of alcohol and xylene before mounting with DPX mountant (Sigma, 
Dorset, UK) for slides using the DAB detection system. Tissues known to express the 
proteins were included in each run as positive controls; negative controls included 
omission of the primary antibody or use of isotype specific controls where appropriate 
(Table 2.2). 
Table 2.2. Details of antibodies used 
Antibody Species Isotype Dilution / 
Concentration 
Supplier Positive 
human control 
tissue 
MelanA Mouse IgG1k 
Mouse 
monoclonal 
1:100 
0.96 µg/ml 
Dako Eye containing 
UM 
Ki67 Mouse IgG1k 
Mouse 
monoclonal 
1:200 
0.4 µg/ml 
Leica Tonsil 
αSMA Mouse IgG1k 
Mouse 
monoclonal 
1:600 
0.1 µg/ml 
Dako Colon 
BAP1 Mouse IgG1k 
Mouse 
monoclonal 
1:200 
1 µg/ml 
Santa 
Cruz 
Pancreas 
CD68 Mouse IgG1k 
Mouse 
monoclonal 
1:200 
0.15 µg/ml 
DAKO Tonsil 
 
2.2.6 Clinical, histopathological and genetic information 
 
Clinical and histopathological information from the primary UM used in 3D spheroid 
assays were provided in an anonymous format by the LOOB (Table 2.3). 
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DNA extracted from the 3D spheroids was analysed for copy number variation of 
chromosomes 1p, 3, 6, and 8 by applying MLPA as described [117]. This was 
performed as part of the Ocular Oncology Molecular Pathology Service by Miss 
Sophie Thornton (University of Liverpool, UK).  
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Table 2.3 Clinical, histopathological and genetic information from primary UM tumours 
E = Enucleation, ED = Endoresection, LR = Local resection, ND = Not detailed, NA = Not applicable L = Loss, N = Normal, G = Gain
  Patient tumour 
 S084-15 S093-15 S104-15 S119-15 S121-15 S125-15 S143-15 S114-15 S145-15 S006-15 S082-15 
Clinical 
information 
Tumour 
location 
Ciliochoroidal Ciliochoroidal Choroidal Choroidal Choroidal Ciliochoroidal Choroidal Choroidal Choroidal Choroidal Choroidal 
Previous 
treatment 
No No No No No No No No No No 
No 
H
is
to
p
a
th
o
lo
g
ic
a
l 
in
fo
rm
a
ti
o
n
 
Specimen 
type 
E E ED E E E LR E E E E 
Cell type Epithelioid Spindle Mixed Mixed Mixed Mixed Epithelioid Mixed Epithelioid Spindle Mixed 
Presence/abs
ence of 
vascular 
loops 
Yes No NA Yes Yes Yes ND Yes Yes Yes Yes 
Mitotic 
count/40HPF 
4 4 NA 3 2 6 2 8 14 3 38 
Presence/abs
ence of 
necrosis 
No No NA No No No No Yes No No Yes 
Macrophages Scattered Scattered ND ND 
Mild 
infiltration 
Heavy 
infiltration 
Numerous Scattered ND Scattered ND 
nBAP1 
protein 
expression 
-ve +ve ND +ve +ve -ve +ve ND -ve +ve -ve 
Genetic 
information 
Chr3 L N N N L L N N L N L 
Chr6p G G N G G G G G N G N 
Chr8q N G N N N G N G G G G 
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2.3 Results 
 
2.3.1 Cell suspension assay 
 
To assess the ability of the UM cell lines to spontaneously from tumour spheroids in 
culture, they were plated in polyHema coated Petri dishes which renders the plates 
non-adhesive. By preventing cell adhesion, the cells are encouraged to migrate 
towards each other. Using this method, the UM cell lines formed loose aggregates of 
varying sizes (Figure 2.2). Collecting the aggregates in this assay proved difficult as 
they would simply disintegrate once any attempt at manipulation e.g. pipetting was 
made. 
 
Figure 2.2. Representative images (200 µm) of UM cell lines grown in suspension. Cell lines 
were plated at 30,000 cells in polyHema coated Petri dishes, in 6 mls UM medium A (as 
described in materials and methods). Images were taken after 10 days incubation. A. MEL270 
cell line formed small dispersed aggregates. B. 92.1 cell line formed loose aggregates 
containing some pigmented cells. C. OMM2.3 cell line formed small and few, dispersed loose 
aggregates. D. OMM1 cell line formed large loose aggregates. 
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2.3.2 Hanging drop assay 
 
In the hanging drop method, UM cell suspensions were plated on a Petri dish lid as 
single droplets. Due to gravitational force, the droplets “hang” from the Petri lid once 
inverted and cells assemble together at the base of the droplet (Figure 2.3 A). In this 
assay, after 4 days of incubation, the 92.1, OMM2.3 and OMM1 UM cells formed 
tumour spheroids of varying size and compactness, 92.1 and OMM2.5 UM cells 
formed more compact spheroids, OMM1 UM cells formed loose spheroids and 
OMM2.3 UM cells formed loose aggregates (Figure 2.3 B). This assay required great 
care and diligence, during the whole process of depositing the droplets to inverting 
the Petri dish lid, and any subsequent manipulation e.g. imaging, feeding and 
collecting the droplets. The majority of the spheroids would disintegrate following any 
manipulation to collect them; in particular, those that had formed less compact 
spheroids, e.g. OMM2.3 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Representative images (scale bar 200 µm) of UM cells in hanging drop assay. A. 
Cells were plated as individual droplets of 7500 cells in 20µl’s UM medium A onto Petri dish 
lid, then inverted. PBS was added to Petri dish to prevent droplets of cells from drying. B. Cell 
lines forming tumour spheroids of varying size and compactness. Images were taken after 2 
and 4 days of incubation, on an inverted microscope at 4x magnification.  
  
39 
 
2.3.3 ULA 96-well plate spheroid assay 
 
ULA 96-well round bottom plates were used to assess the ability of the UM cell lines 
and primary UM cells to form tumour spheroids. UM cells OMM2.3 formed loose 
aggregates (Figure 2.4 B and 2.5 A), which were again difficult to manipulate further, 
since once they were removed from the wells they did not maintain their structure 
(Figure 2.4 C). The UM cell lines OMM2.5 and 92.1 formed more compact spheroids 
(Figure 2.4. B and 2.5 B) however they also failed to maintain their compact structure 
when removed from the wells. In contrast, the primary UM cells S104-15, formed 
compact spheroids in culture and further maintained their 3D spheroid structure when 
removed from the wells for fixation and assessed by IHC (Figure 2.4 C).  
Figure 2.4. Representative images of UM and primary cells in ULA 96 well plate. Cells 
were plated at increasing densities indicated in ULA 96 well round bottom plates to generate 
spheroids. A. ULA 96 well plate showing schematic representation of spheroid formation at 
the base of individual wells. B. OMM2.3 and OMM2.5 cell lines in UM medium A, and S104 
primary cell line in primary cell culture medium plated as spheroids. Images taken at day 7 
using an inverted microscope, at 4x magnification (200µm). C. H&E image of OMM2.3 cells 
showing viable UM cells towards the edge of the spheroid and S104-14 spheroids of plump 
spindle cells at day 7. 
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Based on UM cell line evidence and the initial success with the primary tumour in the 
ULA plate, further assays were performed with this method. Eleven primary UM 
tumour specimens were cultured. The clinical, histopathological and genetic 
information of each patient specimen was recorded (Table 2.4). Of the eleven primary 
UM specimens, six were disomy 3 and five demonstrated chromosome 3 loss. Normal 
chromosome 3 status or a loss of chromosome 3 was irrespective of the cell type 
(Table 2.4). Only one case (S114-15), which was a enucleation with mixed cell type 
and normal chromosome 3 status, failed to grow in culture. The remaining ten 
successfully grew in 2D culture and were further utilised for 3D spheroid culture. 
These cases were enucleations with one endoresection (S104-15) and one local 
resection (S143-15). Six of these UM were of mixed cell type, three were epithelioid, 
and the remaining two were spindle. Six of the ten cases formed tumour spheroids in 
the 3D culture assay (Figure 2.5 A - F). Although the other four cases were 
successfully cultured in 2D, they formed aggregates or a flat sheet of cells when 
plated for 3D culture and failed to form spheroids, it was unclear why these six UM 
failed to grow as tumour spheroids.   
At the earlier time point of 3 days and at the lower plating cell density, in the majority 
of cases UM primary cells formed loose aggregates or loose spheroids. In particular, 
the UM case S119-15 demonstrated rather dispersed cells until day 9 (Figure 2.5 F). 
However, at 6 and 9 days of culture and at the higher plating densities, the primary 
UM cells begin to form more compact structures (Figure 2.5 A - F). 
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Figure 2.5. Primary UM cells in ULA 96 well plates. A. S084-15, B. S093-15, C. S104-15, D. S121-15, E. S125-15, F. S119-15 were digested and cultured in a 
tissue culture flask in culture medium B. Following growth of primary human cells to 80% confluence cells were harvested and plated in ULA 96 well plates at 
the indicated cell densities in 100 µl of primary cell culture medium. Spheroids were imaged and measured at days 3, 6 and 9 using the Axio ObserverZ1 Zeiss 
Microscope.
A B C 
D E F 
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The IHC analysis of each primary UM specimen allowed for the establishment of an 
immunophenotype for each case. For example, the specimen S093-15 can readily be 
analysed and studied by comparing the tumour cells in the cross-section of the 
enucleated eye with those in the 2D and 3D cultures. Furthermore, comparisons can 
be made of nuclear BAP1 and MelanA expression (a classic marker of the 
melanocytic lineage, Ki67 growth fraction, and macrophages. The S093-15 
melanocytes seen in the sections of the enucleated eye were predominantly spindle 
in shape; however, a mixed cell type was observed when isolated cells were cultured 
in 2D. Interestingly, when grown in 3D culture, these UM cells were more spindle in 
shape (Figure 2.6 and table 2.4 A). This was also observed with the case S125-15, 
where the tumour cells were of mixed cell types within the original tumour sections, 
had a spindle cell morphology in 2D culture, and were of mixed cell type when grown 
in 3D culture (Table 2.4 D). 
 
 
 
 
 
 
 
Figure 2.6. S093-15 tumour cell types. A. H&E Cross section of enucleated patient eye. B. 
Higher power of spindle tumour cells within patient eye (macrophages highlighted with arrows). 
C. Mixed cell type of tumour cells cultured in 2D. D. Spindle cell type of tumour cells in cultured 
in 3D. 
6 mm 
200 µm 
50 µm 
B 
C 
30 µm 
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In addition to similarities in UM cell type observed between the primary tumour and 
the 3D spheroid, the presence of macrophages was also retained. For example in 
case S093-15, macrophages are seen throughout the original tumour (Figure 2.6 B 
arrows) and are also present in the 3D spheroids (Figure 2.7 A). These macrophages 
were also present in both primary tumour and tumour spheroids in S084-15, S121-15 
and S125-15 cases as indicated by CD68PG staining (Figure 2.7 A – D). In the case 
of S104-15, analysis of the original tumour for the presence of macrophages was not 
possible as the tissue was very fragmented since it had been obtained via an 
endoresection procedure. Despite this, these UM cells successfully grew as 3D 
spheroids and IHC analysis clearly showed the presence of macrophages (Figure 2.7 
E). Although macrophages were not reported for S119-15 case (Table 2.3), they were 
observed in the 3D tumour spheroids (Figure 2.7 F).  
 
Figure 2.7. CD68 staining of tumour spheroids. Cross section of the tumour spheroids 
showing distinct macrophages (arrows) in A. S093-15, B. S084-15, C. S121-15, D. S125-15, 
E. S104.15, F. S119.15. 
500µm 
500µm 
500µm 
500µm 
500µm 
500µm 
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Interestingly after 6 days in culture, and more evidently at the higher cell densities of 
8,000 and 16,000 cells per well, necrotic centres were observed in some of the more 
compact spheroids (Figure 2.5 B).  This is evident in other tumour spheroids, where 
a gradient of proliferation develops as spheroids become more compact, correlated 
with tumour hypoxia [106]. Not all of the UM tumour spheroids developed a necrotic 
centre; in some cases the spheroids would form compact shapes after 9 days in 
culture (Figure 2.5 E and F). When the UM spheroids were analysed further, 
proliferating cells could be observed towards the edges of the spheroids and less so 
in the centre (Figure 2.8). 
 
 
 
 
Figure 2.8. Cross section of primary UM spheroids (S093-15) at day 9. H&E image showing 
a less proliferative core (arrows) as also indicated by lower Ki67 staining in adjacent image, in 
this region compared to the outer regions. 
 
The presence or absence of nuclear BAP1 was consistent between the original patient 
tumour and the 3D spheroid in all cases (Table 2.4 and Appendix 1 – 6). Surprisingly, 
however, three cases that displayed nuclear BAP1 staining in the original tumour 
and/or 3D spheroid, demonstrated a loss of nuclear BAP1 expression in 2D culture 
(Table 2.4 A – F). The genetic status of the primary UM for chromosomes 3, 6 and 8 
was consistent with the data obtained from the 3D spheroids (Table 2.4 A – F).
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Table 2.4. Histopathological and genetic information from the original primary UM tumour and in 2D and 3D culture 
 
NA= not applicable, N= normal, G = gain, L = loss, ++++ = 80 – 100% positive staining, +++ = 60 – 80% positive staining, ++ = 40 – 60% positive staining. 
 
B A C 
D E 
S093-15 2D culture 3D culture
Cell type Spindle Mixed Spindle
Macrophages Scattered NA Present
melanA +ve ++++ ++++
nBAP1 protein expression +ve -ve +ve
Chr3 N ND N
Chr6p G ND G
Chr8q G ND G
S104-15 2D culture 3D culture
Cell type Mixed Spindle Spindle
Macrophages ND NA Present
melanA +ve +++ ++++
nBAP1 protein expression ND -ve +ve
Chr3 N ND N
Chr6p N ND N
Chr8q N ND N
S119-15 2D culture 3D culture
Cell type Mixed Spindle Spindle
Macrophages ND NA Present
melanA +ve ++ ++++
nBAP1 protein expression +ve -ve +ve
Chr3 N ND N
Chr6p G ND G
Chr8q N ND N
S125-15 2D culture 3D culture
Cell type Mixed Spindle Mixed
Macrophages
Heavy 
infiltration
NA No
melanA +ve ++++ +++
nBAP1 protein expression -ve +ve -ve
Chr3 L ND L
Chr6p G ND G
Chr8q G ND G
S121.15 2D culture 3D culture
Cell type Mixed Nd Spindle
Macrophages
Mild 
infiltration
ND Present
melanA +ve ND ++++
nBAP1 protein expression +ve ND +ve
Chr3 L ND U
Chr6p G ND N
Chr8q N ND G
S084-15 2D culture 3D culture
Cell type Epithelioid ND Epithelioid
Macrophages Scattered ND Present
melanA +ve ND ++++
nBAP1 protein expression -ve ND -ve
Chr3 L ND ND
Chr6p G ND ND
Chr8q N ND ND
F 
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2.4 Discussion  
 
Development of in vitro models for studying cell biology and cell physiology has been 
of great importance in cancer research and drug discovery, as well as the emerging 
fields of tissue engineering and regenerative medicine. The traditional 2D methods of 
mammalian cell culture have several limitations, and it has become increasingly 
recognised that cells grown in a 3D environment more closely represent normal 
cellular function because of the increased cell-to-cell interactions present [108].  
The use and advantages of the different 3D culture methods that have been described 
in the literature were outlined in the introduction of this chapter; however these 
methods do present with some limitations. Due to constant mixing in the spinner flask 
method, cells cannot be visualised as they aggregate, and furthermore, it may not be 
a useful method for cells that are sensitive to shear forces. Spheroids formed in the 
liquid overlay method are often heterogeneous in size and shape, and as a result a 
uniform homogenous set of spheroids cannot always be obtained for comparison and 
further studies [108]. This was consistent with the results obtained with the UM cell 
lines. The hanging drop assay requires diligence and care as the droplets are in close 
vicinity to each other and any sudden movements to the Petri dish can cause the 
droplets to fall or to join together. In addition, tracking these spheroids during culture 
can be difficult and further manipulations such as media change or the addition of 
drugs can be challenging.  
The most efficient method used in this chapter was the ULA 96-well plates for the 
culture of the 3D spheroids. UM primary cells in particular formed individual spheroids 
in each well of the plate and were easily imaged and further manipulated. 
Furthermore, these tumour spheroids retained many of the features of the original 
patient tumour, including cell morphology, nuclear BAP1 expression and the presence 
or absence of macrophages. Macrophages are a key feature of UM, associated with 
a poorer prognosis in UM patients [118]. Surprisingly, these macrophages were found 
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in the tumour spheroids, even after their culture in 2D. The majority of the 
macrophages were found closer to the edges of the tumour spheroids, further 
investigation could establish whether these macrophages would infiltrate further into 
the spheroid chore with a longer period of time in culture, or remain on the edges of 
the tumour spheroids. It was not possible to obtain further histopathological 
information for case S104-15, since an endoresection was performed for this patient 
and since only a small sample, only a cytospin was made, which is limiting with 
respect to the amount of IHC that can be performed. When cultured in 3D and 
analysed further by IHC however, macrophages were identified, as a result providing 
a more complete profile for this tumour based on culture as spheroids. 
Since BAP1 plays a key role in UM metastasis and is used as a prognostic marker 
[28], as described in Chapter 1, it was important to assess its expression in the 
different culture environments. In both the original tumour and in the spheroids, 
nuclear BAP1 expression remained the same. However, this was not the case in 2D 
culture as tumours originally expressing BAP1 lost this expression in 2D culture (Table 
2.4 A and C).  The difference in expression highlights the importance of the correct 
environment for tumour growth, and the more representative 3D environment.  This 
representative environment is further noted in the UM tumour spheroids at the later 
days in culture; when observed under a microscope, the spheroids present with a 
lighter outer layer and a darker inner centre (Figure 2.5 B). As spheroids grow in size, 
the inner cells become necrotic; this is paralleled by a decrease in Ki67 cell 
proliferation staining in the primary UM spheroids. After further IHC analysis, the UM 
spheroids showed a less proliferative core compared to the more proliferative outer 
layer, similar to micrometastases and avascular tumours [119]. When spheroids reach 
a critical size of ≥ 500 µm in diameter, they begin to form gradients that more faithfully 
mimic in vivo solid tumours, including an outer proliferating zone an inner quiescent 
zone, and a central necrotic core [119]. In order to grow further, tumours require a 
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blood supply, as a result a cascade of signalling factors are activated to supply the 
proliferating cancer cells with oxygen [120].  
The 3D spheroid culture system, further offers the unique opportunity to culture cancer 
cells with various cell types. This co-culture system, allows interactions that cause the 
cells to acquire morphological and cellular characteristics relevant to in vivo tumours. 
Holliday and colleagues utilised this system by co-culturing breast cancer cells with 
luminal cells, myoepithelial cells and stromal fibroblasts and reported features in 3D 
similar to ductal carcinoma in situ [121]. Furthermore, breast cancer cells co-cultured 
with fibroblasts showed an invasive phenotype, and formed a tissue more similar to 
primary breast cancer tissue [122]. A co-culture system may provide a great 
advantage in better understanding UM metastasis to the liver. Liver resections are 
uncommon, and culturing liver cells have proven a challenge in research. When 
hepatocytes are cultured in 2D, they lose their differentiation function; however, when 
cultured as spheroids, they retain their polarity, form tight junctions and have 
hepatocyte-like functions [123]. Co-culturing hepatocytes with hepatic stellate cells 
encourages the rapid formation of hepatic spheroids on a modified surface. 
Multicellular spheroids formed via this method retained hepatospecific functions for 
more than two months in culture  [124]. A co-culture spheroid system with UM cells 
and hepatocytes as a future direction in these spheroid assays could shed some light 
into the current questions regarding the preference of UM cells settling primarily in the 
liver. Furthermore, they will provide a platform for drug discovery and the treatment of 
metastatic UM.  
3D in vitro culture systems have been shown to recapitulate the drug sensitivity 
patterns of tumour cells in vivo. Spheroids cultured from a breast cancer cell line had 
a lower IC50 to cisplatinum than the same cells cultured in 2D. Moreover, when treated 
with DNA damaging therapeutic agents, TGF-βs are upregulated in vivo, consistent 
with the treatment of the spheroids; however, similar results were not observed in 2D 
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[125]. In designing effective treatment strategies, tumour heterogeneity introduces 
significant challenges. The difference between the size and necrotic core of the 
tumour spheroids investigated in this chapter is a small reflection of the different 
tumour types in patients. This results in different sensitivities to drugs among different 
patients. Model systems can typically lack the heterogeneity seen in human 
cancers. In order to accurately study tumour heterogeneity, more accurate preclinical 
models are required. The heterogeneity observed among the patient tumour 
spheroids in this investigation, is a step towards recapitulating and understating the 
individual patient tumour and allowing for the assessment of different potential 
therapeutic targets.  
It is unclear why some UM cases in this investigation failed to form tumour spheroids, 
perhaps a larger panel of cases would not only offer an explanation for this, but also 
provide a more representative quantitative data set than that presented here. In 
addition, measuring tumour volume would better demonstrate the reproducibility in 
spheroid size, in particular if the spheroids were to be treated with potential 
therapeutic drugs. This can easily be achieved since there are currently imaging 
systems designed for 96 well plates and measuring spheroids such as the Celigo™ 
cytometer [106]. As well as recapitulating the tumour environment, these 3D tumour 
spheroids can further be utilised for potential therapeutic targets. Since there has 
been no influence on the survival of UM patients with the current treatment options 
for metastasis, discussed in more detail in Chapter 4, these tumour spheroids can 
provide an efficient, simple and reproducible setting with which to assess different 
drugs. Furthermore, to recapitulate the behaviour of the UM tumour spheroids in an 
in vivo environment, they can be utilised as xenografts in animal models described in 
the following chapter.   
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Chapter 3 
 
Chick embryo as a model to study uveal melanoma 
metastasis 
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3.1 Introduction 
 
3.1.1 Historical background 
  
The chick embryo has been widely used in cancer research and has proved itself as 
an essential in vivo model for understanding tumour biology, angiogenesis, metastatic 
spread and drug testing. The history of the chick as a model organism dates back to 
330 B.C.; by opening chick eggs at different stages, Aristotle studied the chick 
development and made detailed observations, recorded in his Historia Animalium. 
Later, in the 17th century, Marcelo Malpighi used the chick embryo to define and 
describe blood vessels, followed in the late 19th century by the first complete atlas of 
chick morphology, Atlas d’embryologie [126]. These advances further led to the 
universally used Hamburger-Hamilton staging system, which illustrates 46 
morphologically distinct stages of chick development beginning with a freshly laid egg 
to a fully developed and hatched chick [127].  
The absence of a full immune system early in chick embryo development has also 
widely contributed to its tractability as a cancer model. In 1911, Francis Peyton Rous 
discovered the Rous Sarcoma Virus; he prepared an extract from a sarcoma found 
on a hen by mincing a sample of the tumour in saline and passing it through a filter to 
eliminate bacteria and tumour cells. He then injected the extract into healthy chickens 
and found that new tumours arose [128]. This ultimately led to the discovery of viral 
oncogenes and fundamentally, changed our understanding of cancer growth and the 
applications of the chick model in human cancer research.   
Following on from Rous and Murphy’s work demonstrating growth of chicken sarcoma 
tumours transplanted on the chorioallantoic membrane (CAM) [129], Murphy 
continued to show successful heterologous transplantations of tumours through 
continuous passage from one egg to another, in a similar manner to the more recently 
described propagation of patient derived xenografts in mice [101]. Furthermore, he 
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demonstrated that although rat tissues could not grow on adult chickens, transplants 
successfully grew on the CAM up to embryonic day 18 of chick development [130, 
131]. These studies revealed the utility of the natural immunodeficiency in this model 
and the CAM has since become a predominant feature of the chick embryo for the 
study of spontaneous metastasis [132].    
3.1.2 Development of the chick embryo 
 
Of particular help to cancer researchers using the chick embryo model is the detailed 
description of the stages of chick embryo development, from the first cleavage division 
through to hatching as defined by Hamburger and Hamilton. Development of internal 
organs commence early in chick development: by embryonic day 2 (E2) the heart is 
beating, and by the end of E3 the limb buds for the wings and legs are visible. Between 
E5 and E6 formation of the reproductive organs takes place. The embryo begins to 
move into position for hatching at E14 and enters a further growth phase before 
hatching on E20 - E21 [133].  
Of particular relevance to this chapter are the timing of eye and the liver development 
in the chick embryo. The liver is formed from both the mesoderm and endoderm and 
the liver primordium is visible at the end of E2. Haemopoiesis in the liver of the chick 
embryo begins at E7 and peaks at E14. The liver is a closely packed mass of 
dendriform cords and discontinuous sinusoids. In both birds and mammals, the 
discontinuous linings of the sinusoids consist of endothelial cells and Kupffer cells 
[134].  
The first sign of eye development, the rudiments of the primary optic vesicles, is 
around E1 – E2 [135]. By E4, the lens has begun to acquire its shape, and around 
E7, the ciliary body which develops close to the lens, secretes the fluid of vitreous 
chamber. The iris and the retina also form around E7 and at this stage the choroid 
begins to develop pigment and the eyelids start to form [135].  
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3.1.3 Development of the Chorioallantoic membrane 
 
The CAM, a highly vascular extraembryonic membrane, begins to form between E3 
and E4 from the fusion of the chorion and the allantois [132]. The chorion is the 
outermost membrane that surrounds an embryo and the allantois is a sac-like 
structure that forms part of a developing amniote's conceptus, consisting of all 
embryonic and extra-embryonic tissues (Figure 3.1). The CAM consists of three 
layers: the ectoderm from the chorion that attaches to the shell membrane, and the 
mesoderm and endoderm from the allantois enriched in blood vessels, all of which 
then form a thin transparent collagenous matrix. A fully developed capillary plexus 
has developed by E10, and by E16 the CAM has surrounded the yolk sack pressing 
against the egg shell membrane. This allows it to serve as a set of lungs for the 
developing embryo enabling the exchange of gasses through the pores in the shell 
[136]. The chick immune system does not begin to function until around two weeks 
into its development. By E10 and E12 respectively, monocytes and macrophages can 
be found and from E10 to E15 the two major inflammatory cell types, heterophils and 
monocytes are present. By E18, the chick embryo is fully immunocompetent [137]. 
Figure 3.1. Developing chick embryo surrounded by the chorioallantoic membrane 
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3.1.4 Chick embryo as a model in cancer biology 
  
The chick embryo as a model to study tumour development and metastasis has been 
reported in many different cancers including ovarian, renal, colorectal and prostate 
[138-141]. Studies have used this model in two main experimental approaches 1) 
inoculation of tumour cells directly on to the CAM to study tumour development and 
spontaneous metastasis; and 2) inoculation of tumour cells intravenously as a direct 
metastasis model. 
The CAM has become invaluable in developmental studies and has provided a 
platform for cell intravasation and spontaneous metastasis models. Studies using 
human fibrosarcoma cells showed their capacity to form tumour nodules on the CAM 
as well as in distant portions of the CAM, and also in internal organs by PCR [142]. 
Several important steps of metastasis, including tumour invasion, angiogenesis and 
metastasis have been explored in this assay. Nasopharyngeal carcinoma (NPC), a 
highly invasive and metastatic head and neck cancer has been difficult to study due 
to lack of tissue and in vivo models for this disease. Recently, Xiao and colleagues 
reported 100% tumour formation of four NPC cell lines, and 35 primary tumour 
biopsies after 3 days of inoculation on the CAM, including extracellular matrix 
interaction and induced angiogenesis [143]. 
Chambers and colleagues injected B16F1 cutaneous melanoma cells into the blood 
vessels of the chick embryo CAM at E11 and the tail vein of mice. After 7 and 20 days 
respectively, the chick embryos and mice were examined for tumour formation. The 
total number of tumours per animal was much greater in the chick than in the mouse 
(~25 fold) [144]. In another study B16F1 cells were injected into the optic cup of the 
chick embryo at E3.5. Histological examination demonstrated that some cells 
remained at the site of transplantation while other cells formed tumours and invaded 
the choroid. Furthermore, the malignant growth of the melanoma cells in the optic cup 
was enhanced by bone morphogenetic protein-2 (BMP-2), highlighting the utility of 
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orthotopic studies and the ease of access and manipulation in this model [145]. 
B16F10 tumour cells inoculated into the chorioallantoic vein at E10 disseminated 
throughout the vascular system of the chick and more than 80% of injected cells 
survived the microcirculation and successfully extravasated by 1 - 3 days later [146]. 
Therefore within a few days after inoculation, tumour cells can be identified in the 
CAM distant from the inoculation site and in organs. For example, following injection 
of leukaemia cells, they were found engrafted in the chick brain, similar to central 
nervous system involvement in the human disease and in hematopoietic organs, as 
early as 7 days post injection, in contrast to the 4 weeks and more required for 
engrafting severe combined immunodeficient mice [147]. As early as 10 minutes after 
intravenous injection of fluorescently labelled B16-F10 cells, they were found arrested 
in the capillary bed. Six hours later, they had changed their shape and spread in close 
contact with the capillary wall [148]. 
Advances in imaging technologies have made it possible to visualise vascular 
perfusion, vascularisation of the CAM and the distinct steps of angiogenesis. 
Following small nanoparticles through the vascular beds that feed solid tumours can 
predict how intravenously administered drugs will localize within tumours and their 
surrounding tissues. Imaging tumour vascular dynamics in the CAM is faster, easier 
and less expensive than in mammals, promoting its utility for screening drugs or new 
designs for drug carriers and potential targeting agents [149]. Furthermore, GFP-
labelling of cells enables them to be easily visualised in this model, compared to the 
original PCR methods. Lewis lung carcinoma cells stably expressing GFP were 
injected at E12. The GFP-labelled cells were visualised by fluorescence after 7 days 
in the brain, heart, and the sternum, with the most frequent site being the brain. The 
E12 chick embryos were injected intravenously with GFP-Lewis lung cancer cells 
along with two agents (streptokinase and gemcitabine) either alone or in combination. 
The combination of these agents inhibited metastasis at all sites, showing that the 
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GFP-tumour chick-embryo model should be very useful for rapid screening of anti-
metastatic agents [149]. 
To date, there are only three studies that have used UM cells and the chick embryo 
as a model to study this disease. Luyten and colleagues microinjected 102 - 103 UM 
cells into the developing eye of twenty embryos. These cells were cultivated from the 
subcutaneous metastatic lesion of a 46 - year old patient who had undergone 
enucleation 28 years earlier. At E19, the eyes were removed for histological 
examination: 18 of the 20 injected embryos had survived; four showed intraocular 
tumour growth. UM cells were observed adherent to the ciliary body, along the hyaloid 
artery and tunica vasculosa lentis. Immunohistochemical analysis showed positive 
expression of S100P and HMB45 highlighting UM cells in these regions. UM cells 
were not reported by these authors in the choroid. Interestingly, when they repeated 
the same experiments injecting human skin melanoma cells into the optic cup, these 
cells had also infiltrated the choroid [150]. 
Berube and colleagues used the CAM assay to study the tumourigenic potential of 
four cell lines; SP6.5, SP8.0 and TP31 derived from the primary UM of three different 
patients, and H79 cells derived from a metastatic UM in the liver. All four cell lines 
formed vascularised tumour masses on the CAM following inoculation of 5 x106 cells 
at E10 for seven days; however, histological analysis of these tumours was not 
reported [151]. 
Laurent and colleagues, examined the effects of protein tyrosine phosphatase type 
IV A member 3 (PTP4A3), when introduced into the OCM1 UM cell line, on tumour 
cell dissemination using the CAM assay. They reported increased migration and 
invasiveness in the chick femur, although no information was provided with regard to 
tumour formation and mass of the OCM1 cells, or metastasis to any organs [152]. 
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The aim of this chapter was to investigate the chick embryo as an in vivo model to 
study UM tumour development, intravasation, extravasation and metastatic 
colonisation. To achieve this two approaches were used: 1) various UM cell lines were 
grafted onto the CAM as a spontaneous metastasis model, and 2) UM cell line 
injections were performed into the chick embryo circulation mimicking a direct 
metastasis (or dissemination) model. 
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3.2 Materials and Methods 
 
3.2.1 Chick egg preparation 
 
Fertilised white leghorn chicken eggs (obtained from Lees Lane poultry, Neston, UK) 
were incubated at 37°C. At embryonic day 2 (E2) or E3 a small incision was made at 
one end of the egg using a 19 gauge needle (Terumo) and syringe and approximately 
4 ml of albumin was removed to detach the embryo and surrounding vessels from the 
shell. A small rectangular window was then cut into the “top surface” of the egg shell 
using a Power Craft PKW-160N Combitool and the window then sealed using Scotch 
Magic adhesive tape (Figure 3.2). Eggs were then further incubated at 38°C and 40% 
humidity.  
 
Figure 3.2. Outline of chick embryo egg preparation for CAM and injection assays. A. 
Fertilised eggs are incubated at 37°C. B. At E3, approximately 3ml of albumin is removed with 
a 5ml syringe and 18-gauge needle to lower the CAM. C. A small window is cut into the egg 
shell using a rotating disc drill. D. The window is sealed to allow normal development until 
experimental day where it will provide access for CAM laceration and tumour cell injection. E. 
Eggs are incubated at 38°C and 40% humidity. 
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3.2.2 Cell preparation 
 
UM cells 92.1, MEL270, OMM1 and OMM2.3 were cultured and harvested as 
described in Chapter 2. The breast cancer cell line MCF-7, was cultured in DMEM 
(Sigma, Dorset, UK) supplemented with 10% fetal calf serum (FCS; PAA 
Laboratories), 2 mM l-glutamine (Sigma), and antibiotics (penicillin 50 IU/ml, 
streptomycin 500 µg/ml). MCF-7 cells were used to compare the behaviour of a non-
mesenchymal cell line to the mesenchymal UM cell lines. 
The UM and MCF-7 breast carcinoma cells were transduced with an enhanced green 
fluorescent protein (EGFP)-expressing HIV-based lentivirus. In brief UM cell lines 
plated at 500 cells/ well (24 well plate) were transduced and following an incubation 
of 24 hours, the lentivirus was removed and transduction efficiency was examined 
microscopically. Wells containing >90% EGFP expressing cells were propagated and 
banked down for all future experiments. Transducing the cells was kindly carried out 
by Dr Anne Herrmann. 
3.2.3 CAM inoculation 
 
GFP-labelled 92.1, OMM1, MEL270, OMM2.3 UM cells and MCF-7 breast carcinoma 
cells were counted using a haemocytometer and 2 x 106 cells were removed and 
pelleted at 1500rpm for 1 minute. A small volume of RPMI (approximately 3 μl) was 
mixed with each pellet to create a wet pellet and facilitate pipetting. 
Cell pellets were kept on ice and occasionally re-triturated by flicking the tube. At E7, 
the junction of two or more small blood vessels was selected as the graft site. The 
vessels were then gently traumatised using a pipette tip to induce a small bleed and 
the wet cell pellet was introduced on-to the site. A minimum of 5 embryos underwent 
inoculation in each experimental replicate. Embryos were incubated until E14 at which 
point the CAM was observed under a Leica M165 FC fluorescence microscope for 
the presence of tumour nodules. Tumour nodules formed on the CAM were imaged 
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and dissected from the surrounding membrane and fixed in 10% neutral buffered 
formalin overnight. All CAM inoculations experiments were replicated (Appendix 7). 
3.2.4 Chick embryo injections 
 
GFP-labelled 92.1, OMM1, MEL270, OMM2.3 UM cells and MCF-7 breast carcinoma 
cells were harvested from culture flasks using 0.05% trypsin/ETDA (Life 
Technologies, Paisley, UK) and centrifuged at 1500 for 2 minutes. The resulting cell 
pellet was then resuspended as single cells at a density of 1x105 cells/µl in RPMI 1640 
(Life Technologies) containing 0.05% fastgreen (Sigma). 
Cells were kept on ice and occasionally re-triturated by flicking the tube. Borosilicate 
glass capillary tubing (thin wall with filament, Harvard Apparatus Ltd., Kent, UK) was 
pulled under heat (settings: heat 580, velocity 15, pull 130, time 15, pressure 20; 
Sutter Instrument Co.) to produce needles for microinjection. The needles were then 
snapped using dissecting forceps to create a fine needle end allowing for cell 
suspension uptake.  At E7, approximately 2μl of the cell suspension was injected by 
mouth pipetting (Sigma) directly into the chick embryo circulation under a stereo 
microscope. A minimum of 5 embryos underwent injection in each experiment 
replicate. Embryos were then incubated until E14 at which point they were dissected 
under a Leica M165 FC fluorescence microscope. Organs containing GFP-labelled 
cells were imaged, and subsequently removed and fixed in 10% neutral buffered 
formalin overnight. 
The formalin fixed tissues were then placed in tissue cassettes before being loaded 
onto the BAYER VIP E300 tissue processor. The tissues underwent dehydration in a 
series of alcohol and xylene incubations before being finally maintained in hot wax 
ready for embedding. Tissues were then embedded in paraffin by careful orientation 
in the wax to fix them in the centre of the block.  
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3.2.5 Histological assessment and immunohistochemistry 
 
Sectioning and immunohistochemical assays were performed as described in 
Chapter 2.  
Tissues known to express the proteins of interest were included in each run as 
positive controls; negative controls included omission of the primary antibody or use 
of isotype specific controls where appropriate (Table 3.1). 
Table 3.1. Details of antibodies used. 
Antibody Species Isotype Dilution / 
Concentration 
Supplier Positive 
human 
control tissue 
MelanA Mouse IgG1k 
Mouse 
monoclonal 
1:100 
0.96 µg/ml 
Dako Eye containing 
UM 
Ki67 Mouse IgG1k 
Mouse 
monoclonal 
1:200 
0.4 µg/ml 
Leica Tonsil 
αSMA Mouse IgG1k 
Mouse 
monoclonal 
1:600 
0.1 µg/ml 
Dako Colon 
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3.3 Results 
 
3.3.1 Chick embryo CAM inoculation 
  
Following inoculation of GFP-labelled 92.1, OMM1, MEL270, OMM2.3 and MCF-7 
cells onto the CAM at E7, tumour nodule formation was assessed at E14. The success 
rate/tumour nodules forming efficiency, as determined by size and histological 
assessment of nodule viability, was recorded (Appendix 7). MEL270, OMM2.3 and 
MCF-7 cell lines failed to form tumour nodules on the CAM. The tumour nodule 
forming efficiency of 92.1 and OMM1 cells varied between experiments ranging from 
a 30 – 100% success rate (Appendix 7). After the seven days of incubation at E14, 
UM cells were not observed in any internal organs, either using the fluorescence 
microscope or on histological examinations. 
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3.3.1.1 CAM inoculation of 92.1 cells 
 
92.1 UM cells formed nodules that were pigmented and surrounded by a network of 
blood vessels (Figure 3.3).  
Figure 3.3. Macroscopic detection of 92.1 cell line tumour nodule formed in the CAM 
assay. A. 92.1 uveal melanoma cells formed a visible nodule on the CAM at E14, 7 days 
following cell grafting, arrow shows pigmented tumour nodule. B. Fluorescent image showing 
GFP-labelled 92.1 cells within nodule in ovo. C. Tumour nodule dissected from embryo with 
surrounding CAM tissue for further analysis. D. Fluorescent image of dissected tumour nodule.  
 
Histological analysis of the tumour nodule sections clearly showed the tumour nodule 
surrounded by the CAM tissue (Figure 3.4 A). Melan A was expressed by some of the 
cells within the CAM nodule (Figure 3.4 B) and a small number of MelanA positive 
tumour cells were also seen in the surrounding CAM tissue (Figure 3.4 C). αSMA 
staining highlighted the presence of blood vessels within the tumour nodule (Figures 
3.4 D and 4E) and nuclear Ki67 staining within the tumour nodule indicated the 
presence of large numbers of viable proliferating cells (Figures 3.4 F and 3.4 G). 
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Figure 3.4. Immunohistochemical analysis of a representative 92.1 tumour nodule 
formed in the CAM assay. A. H&E-stained cross-section of the 92.1 tumour nodule on the 
CAM at E14. B. MelanA positive cells within the tumour nodule. C. High power image of 
MelanA positive tumour cells located in the surrounding CAM tissue. D. Cross section of 
tumour nodule stained with αSMA showing blood vessels within the tumour nodule. E. High 
power image of individual blood vessel within the tumour nodule. F. Nuclear Ki67 expression 
highlighting proliferating tumour cells. G. High power image of Ki67 nuclear staining. 
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3.3.1.2 CAM inoculation of OMM1 cells 
 
Unlike the nodules formed with the 92.1 cell line, OMM1 tumour nodules were not 
pigmented. A network of blood vessels was also observed surrounding the nodules 
(Figure 3.5). 
 
Figure 3.5. Macroscopic detection of OMM1 cell line tumour nodule formed in the CAM 
assay. A. OMM1 uveal melanoma cells formed a visible non pigmented nodule (arrow) on the 
CAM at E14, 7 days following cell grafting. B. Fluorescent image showing GFP-labelled OMM1 
cells within nodule in ovo. C. tumour nodule dissected from embryo with surrounding CAM 
tissue for further analysis, arrow shows large blood vessel ex ovo. D. Fluorescent image of 
dissected tumour nodule. 
Histological analysis of the tumour nodule sections clearly showed the tumour nodule 
surrounded by the CAM tissue (Figure 3.6 A). Melan A was expressed by some of the 
cells within the CAM nodule (Figure 3.6 B) and a small number of MelanA positive 
tumour cells were also seen in the surrounding CAM tissue (Figure 3.6 C). αSMA 
staining highlighted the presence of blood vessels within the tumour nodule (Figures 
3.6 D and 3.6 E) and nuclear Ki67 staining within the tumour nodule indicated the 
presence of large numbers of viable proliferating cells (Figures 3.6 F and 3.6 G). 
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Figure 3.6. Immunohistochemical analysis of a representative OMM1 tumour nodule 
formed in the CAM assay. A. H&E-stained cross-section of the OMM1 tumour nodule on the 
CAM at E14. B. MelanA positive cells within the tumour nodule. C. High power image of 
MelanA positive tumour cells located in the surrounding CAM tissue. D. Cross section of 
tumour nodule stained with αSMA showing blood vessels within the tumour nodule. E. High 
power image of individual blood vessel within the tumour nodule. F. Nuclear Ki67 expression 
highlighting proliferating tumour cells. G. High power image of Ki67 nuclear staining.  
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3.3.2 Chick embryo injections  
 
Following direct injection of GFP-labelled 92.1, OMM1, MEL270, OMM2.3 and MCF-
7 cells into the chick circulation at E7, their movement and colonisation of internal 
organs was assessed at E14 (Table 3.2). MEL270, OMM2.3 and MCF-7 cell lines 
failed to form metastatic deposits in any of the organs examined at E14. 92.1 and 
OMM1 cells, however, were found in most neural crest-derived tissues and the most 
frequent colonisations occurred in the liver and eye.  
Table 3.2. Distribution of 92.1, OMM1, MEL270, OMM2.3 UM, and MCF7 breast cancer cell 
lines within chick embryo organs at E14. 
+++ = 70 - 100% of embryos examined had GFP-labelled cells in organ, ++ = 40 - 70%, + = 
1 – 40%, - = no tumour cells observed. 
 
3.3.2.1 Chick embryo injections of 92.1 cells 
 
92.1 UM cells were found in the liver and could be seen macroscopically under a 
fluorescence microscope upon dissecting the chick embryo at E14 (Figure 3.7 A and 
3.7 B). Histological analysis of the liver sections showed numerous infiltrating tumour 
cell aggregates of varying sizes next to blood vessels that stained positively for 
MelanA (Figures 3.7 D and 3.7 E). A small number of cells within each foci stained 
positively for Ki67, indicating ongoing proliferation. Ki67 does not stain chick cells 
[153] hence proliferating cells are confirmed tumour cells (Figure 3.7 F and 3.7 G). 
Chick tissue 92.1 OMM1 MEL270 OMM2.3 MCF-7 
Liver +++ +++ - - - 
Eye +++ +++ - - - 
Lungs - - - - - 
Spleen - - - - - 
Heart + - - - - 
Gut + + - - - 
Kidney + + - - - 
Brain ++ ++ - - - 
Number of embryos 
examined 
19 15 10 10 10 
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Cells were also abundant in the eye of the developing chick embryo and these could 
be clearly visualised under the fluorescence microscope (Figure 3.8 B). When further 
dissecting the anterior part of the eye, UM cells were found in the ciliary body and iris, 
as confirmed by MelanA staining (Figures 3.8 D and 3.8 E). Furthermore, cross 
section of the whole eye and close examination of the choroid revealed infrequent UM 
cells within this compartment (Figure 3.8 F). 
 
Figure 3.7. Detection and immunohistochemical analysis of 92.1 GFP-labelled UM cells 
in the chick embryo liver at E14. A. Macroscopic image of a dissected chick embryo liver at 
E14. B. Detection of 92.1 GFP-labelled cells in the chick embryo liver under fluorescence. C. 
H&E-stained cross section image of liver. Inset shows higher power of infiltrating melanoma 
cells (arrows). D. MelanA staining of the tumour cells within the liver showing adjacent blood 
vessels (arrows). E. High power image showing escaping tumour cells from blood vessel 
(arrow). F. A low Ki67 proliferation index is also visible (arrow). G. High power image showing 
proliferating tumour cells.   
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Figure 3.8. Homing of 92.1 GFP-labelled UM cells to the chick embryo eye. A. 
Macroscopic analysis of a dissected chick embryo eye. B. GFP-labelled 92.1 cells injected at 
E7 are visible in the anterior. C. Cross section of anterior segment of eye showing MelanA 
positive cells within the iris. D and E. High power image of MelanA positive tumour cells within 
the iris (arrows). F. H&E cross section of whole eye, inset shows melanoma cell within the 
choroid (arrow). 
 
70 
 
3.3.2.2 Chick embryo injections OMM1 cells 
 
Similar to 92.1 cell injections at E7, OMM1 cells were found predominantly in the chick 
embryo liver at E14. These were clearly visualised using a fluorescence microscope 
and further with MelanA staining. Larger groups of infiltrating OMM1 cells compared 
with 92.1 cells were identified adjacent to blood vessels in the liver. A small number 
of proliferating cells can also be seen as indicated by Ki67 staining (Figure 3.9). 
OMM1 cells were also abundant in the eye of the embryo and these could clearly be 
visualised under the fluorescence microscope. When further dissecting the anterior 
part of the eye, aggregates of cells were found in the iris and ciliary body, and were 
confirmed by MelanA staining (Figure 3.10). 
Figure 3.9. Macroscopic detection and immunohistochemical analysis of OMM1 GFP-
labelled UM cells in the chick embryo liver at E14. A. Macroscopic images of a dissected 
chick embryo liver at E14. B. Detection of OMM1 GFP-labelled cells in the chick embryo liver 
under fluorescence. C. H&E-stained cross section image of liver. Inset shows higher power of 
infiltrating melanoma cells surrounding the blood vessel. D. MelanA staining of liver showing 
tumour cells across the liver, particularly adjacent to blood vessels (arrows). E. High power 
image showing extravasation of tumour cells from blood vessel (arrow). F. A low Ki67 
proliferation index is also visible (arrows). 
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Figure 3.10. Homing of OMM1 GFP-labelled UM cells to the chick embryo eye. A. 
Macroscopic analysis of a dissected chick embryo eye. B. GFP-labelled 92.1 cells injected at 
E7 homed to the uveal tract by E14. C. Cross section of anterior part of eye showing MelanA 
positive cells within the ciliary body and iris of the uveal tract. D and E. High power image of 
MelanA positive tumour cells within the iris (arrows). 
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3.4 Discussion 
 
The chick embryo model has been used successfully to date in a limited number of 
studies assessing the ability of UM cells to; undergo orthotopic growth in the chick 
eye, form tumour masses on the CAM and undergo dissemination via the chick 
circulation to internal organs. This chapter has highlighted that the chick embryo 
model can be used successfully for xenografting UM cells onto the CAM as well as 
direct injection and survival of UM cells in the circulation, facilitating the biological 
analysis of many aspects of tumour development and metastasis. 
UM can be characterised by chromosomal aberrations and genetic mutations that are 
either early events in tumour development i.e. GNAQ and GNA11 mutations or that 
influence the metastatic capacity of the UM cells, in particular loss of one copy of 
chromosome 3, BAP1 and SF3B1 mutations, as discussed in Chapter 1. To date, the 
published studies examining UM cells in the chick embryo model have either failed to 
recapitulate this genetic landscape, having instead BRAF mutations that call into 
question the origin of the tumours [152], or detailed histological examination of the 
tumours formed has not been performed [151]. Berube and colleagues used three cell 
lines derived from enucleated UM and one from a UM metastasis to the liver [151]. 
However, one of the cell lines, SP6.5, harbours a BRAF mutation, which is found in 
cutaneous melanomas and not in UM [103]. In this study, two of the four UM cell lines 
examined, 92.1 (GNAQ mutants) and OMM1 (GNA11 mutant), formed vascularised 
tumour masses on the CAM. Of interest, the two cell lines failing to form tumour 
masses on the CAM, MEL270 (GNAQ mutant) and OMM2.3 (GNAQ mutant) were 
derived from the primary UM and metastasis of the same patient. As a result, a 
correlation between the G protein mutation status and the ability of the cell lines to 
form tumour masses could not be made. However it is not of great surprise that not 
all the UM cell lines failed to form tumour masses on the CAM tissue. Balke and 
colleagues screened eight osteosarcoma cell lines for their ability to form vascularized 
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tumours on the CAM. They reported that three out of these eight cell lines were 
successful in forming nodules on the CAM [154]. As in Balke’s investigation and in 
this study, the inability of all the cell lines to form tumour masses on the CAM 
highlights the importance of continued baseline analyses using a larger panel of well-
characterised UM cell lines, as well as primary cell cultures, covering the spectrum of 
genomic and phenotypic alterations observed in UM patients.  
While spontaneous metastases have been observed following the topical inoculation 
of mouse tumours on the CAM, most tumours do not give rise to spontaneous 
metastases [50]. Similarly the UM cells in this chapter, when inoculated onto the CAM, 
did not spontaneously metastasise to any organs within the chick embryo, despite 
forming tumour nodules surrounded by blood vessels after only 7 days of incubation. 
Degradation and penetration of basement membranes and their underlying stroma 
are hallmarks of tumour invasion and metastasis [155]. It is possible that invading the 
superficial epithelial layer of the CAM could be achieved by incubating the chick 
embryo eggs until a later embryonic stage; in this way allowing the cells more time to 
intravasate the CAM tissue and escape into the blood stream. Indeed, MelanA 
positive UM cells were observed outside the large tumour nodule that formed on the 
CAM (Figure 3B).  Earlier steps in inducing this invasion from the CAM and certain 
characteristics of cell lines such as their ability to release proteases can also provide 
a “push” to promote metastasis. For example, Deryugina and colleagues 
demonstrated the existence of two variants of fibrosarcoma cells with different 
intravasation capacity on the CAM. They showed that specific inhibition in the variant 
with the higher invasion capacity of matrix metalloproteinase-9 (MMP-9) expression 
and activity with MMP-9 small interfering RNA and anti-MMP-9 monoclonal antibody 
resulted in an increase of intravasation indicating that targeting certain MMPs may 
lead to enhanced malignancy [142]. Other experimental approaches, such as addition 
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of trypsin to the CAM tissue prior to placing tumour cells can assist the cells in 
digesting through the CAM tissue (unpublished work by Dr Diana Moss).  
Increased tumour progression and metastasis have previously been associated with 
hypoxic regions in primary tumours [156], and thus an approach may be to incubate 
the UM cells in hypoxic conditions prior to grafting onto the CAM. One such study 
showed that pre-conditioning neuroblastoma (NB) cells to hypoxia leads to metastasis 
to organs in the chick embryo. NB cells successfully form tumours on the CAM without 
spontaneous dissemination, however after pre-conditioning to hypoxia (1% O2) for 3 
days, they not only formed tumours larger in volume but also metastasised in the chick 
embryo organs, mainly to the gut and the liver [157]. This method may further provide 
insight to better understanding the behaviour and characteristics of metastasising UM 
cells in the liver. 
The tissue composition and accessibility of the CAM for experimental manipulation, 
makes it an attractive preclinical in vivo model for drug screening. Hagedorn and 
colleagues showed that tumour growth with key features of human glioblastoma at 
the cellular and molecular levels occurred in a highly reproducible manner after 
human Glioblastoma multiforme (GBM) cell grafting on the CAM. Subsequent 
treatment of the glioma cells with receptor tyrosine kinase inhibitors abrogated tumour 
growth [139]. The simplicity, rapidity, and low cost of the different assays that can be 
performed with chick embryos strengthen the interest of routinely using this model in 
pharmaceutical technology. 
As with the CAM assays, studies using direct injection methods have failed to use a 
representative panel of UM cell lines and to mimic UM metastasis. Laurent and 
colleagues used the OCM1 cell line to investigate the effect of PTP4A3 
overexpression on tumour cell dissemination [152]. The OCM1 cell line harbours a 
BRAF mutation, this is inconsistent with the spread to the liver that is generally seen 
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in UM patients, as this cell line spread to the chick femur. In another study, Luyten 
and colleagues injected UM cells from a subcutaneous metastasis directly into the 
eye of E3.5 chick embryos, and although cells were found in the ciliary body at E19, 
they weren’t reported in the iris or the choroid. Furthermore, metastasis was not 
reported in any other organs [150].  
Two out of the four UM cell lines used in the chick embryo model, MEL270 and 
OMM2.5, failed to form both tumour nodules on the CAM or produce tumour deposits 
in the chick embryo organs when injected directly into the circulation. Of interest, 
these two cell lines are derived from the same patient; one from the primary UM 
(MEL270) and from a metastatic liver lesion (OMM2.3), suggesting an inherent 
property of the two cell lines and a lack of ability to invade through the epithelial sheet 
of the endothelial cell layer. As shown in this chapter, 92.1 and OMM1 UM cells 
“homed” to organs within the chick embryo, that are representative of tumour 
development and metastatic spread in patients i.e. the eye and the liver (Table 2.1). 
Within the eye, cells were found in the ciliary body, iris and the choroid, all of which 
are the sites human UM cells are found in the patient eye. Within the liver, the cells 
were found adjacent to the blood vessels with metastatic foci throughout the liver in a 
similar manner to multiple UM deposits that are seen in the liver of patients with 
metastatic UM [9]. The tumour cell foci, identified by MelanA immunohistochemistry, 
were located close to blood vessels and Kupffer cells; specialised macrophages found 
in the lumen of liver sinusoids [158]. This is consistent with the presence of metastatic 
UM cells in the perisinusoidal space of the liver, also known as the space of Disse, in 
patient specimens [45]. This similarity is of great importance as latency of UM 
metastatic cells in the liver has long puzzled researchers thus a representative model 
could shed significant insight. Borthwick and colleagues suggested that UM latency 
is due primarily to the inability of cells at metastatic sites to grow [159], consistent with 
low Ki67 staining in the chick embryo liver in this investigation. In this study, cells were 
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also found in other organs outlined in table 2.1, but not observed in the lungs or 
spleen, which are the other sites of UM metastasis. As Borthwick and colleagues 
pointed out, metastasising UM cells must pass through the lungs first [159], however 
details of the steps of metastasis still remain poorly understood, in part because of 
the difﬁculty of direct observation of ongoing in vivo processes. Chambers and 
colleagues have used intravital video microscopy to visualize cells labelled with 
ﬂuorescent beads as they arrest in the microcirculation, extravasate, and form 
micrometastases in the chick embryo. Tumour cell division was seen only after 
extravasation [160]. In a further study, the invasiveness between two murine 
mammary tumour cell lines were investigated and in light of their differences in 
invasiveness, no differences were found between the high- and low-metastatic cell 
lines in either the timing or mechanism of extravasation. However, after extravasation, 
the more metastatic and invasive cells showed a greater ability to migrate to sites 
which favour tumour growth and to replicate to form micrometastases [161]. Therefore 
highlighting the post-extravasation events, migration and growth, as being critical in 
metastasis formation. As discussed previously,  certain genetic alterations, e.g. BAP1 
mutations that are found in the majority of metastasising UM’s, could cause the cells 
to perhaps only migrate to the common sites of metastasis found in UM patients. Thus 
isogenic cell lines or the more recently established BAP1 mutant cell lines would be 
ideal future experimental procedures in this model. 
This chapter has highlighted the many studies and different techniques and methods 
used to investigate a variety of cancers and potential therapeutic treatment using the 
chick embryo model. Not to mention the chick embryo as a brilliant cost efficient 
model; the accessibility of the CAM, the well-vascularized extra-embryonic tissue 
located underneath the eggshell, and its acceptance of xenografted tumour cells all 
make it easy to use. The underlying steps of metastasis in UM are still of question, 
however in an effort to mimic metastasis of UM in the chick embryo model this 
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investigation has successfully shown the metastasis and the similar behaviour of UM 
cells in the liver and the uveal tract of the chick embryo. These experiments have 
provided a baseline for further studies and further for preliminary testing of potential 
new agents to aid molecular-based cancer therapy. 
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Chapter 4 
 
Targeted therapy in MYC amplified uveal melanoma 
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4.1 Introduction 
 
Despite increased knowledge of UM biology and despite the advances in primary UM 
treatment, as discussed in Chapter 1, patient mortality remains high in those who 
develop metastatic disease. Metastatic disease occurs in approximately 50% of UM 
patients. The liver is the main site of metastasis and, due to the disseminated spread 
of the UM cells within the liver, with typically numerous metastatic deposits, liver 
resections are possible in only a small number of UM patients with isolated/solitary 
masses [162]. Unfortunately, only limited improved survival of UM patients with 
metastatic disease has been reported with chemotherapy, such as dacarbazine 
(DTIC) [163], hepatic intra-arterial chemotherapy with fotemustine [164]  or interferon-
α-2a [165]. Thus, there is a lack of effective treatment for metastatic UM.  
Recently, targeted therapy has become a growing part of many cancer treatment 
regimens. For example, the identification of BRAF V600 somatic mutations in 66% of 
cutaneous melanomas [166], led to the development of molecularly targeted 
therapies, which initially improved survival of these patients compared with previous 
treatments [167]. However, BRAF V600 mutations are not present in UM [168]. 
Nevertheless, activation of the MAP-kinase pathway occurs in both cutaneous 
melanoma and UM. In cutaneous melanoma BRAF and NRAS mutations activate the 
MAP-kinase pathway; in UM, this occurs through oncogenic mutations in the G-
protein α-subunits q or 11 [25, 169], which are found in greater than 80% of UM 
(discussed in Chapter 1). These mutations result in activation of Protein Kinase C 
(PKC), and are thought to drive downstream signalling leading to activation of the 
mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated 
kinase (ERK) pathways [170] (Figure 4.1).  
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Figure 4.1. Simplified signalling cascade in GNAQ and GNA11 mutant UM. Hydrolysis of GTP 
results in increased Gα protein. Gα signals to phospholipase C (PLC), activating protein kinase 
C (PKC). The MAP kinase pathway is in turn activated by PKC signal. Phosphatidylinositol-3 
kinase (PI3K, class I) which is upregulated in UM cells, signals through Akt and mammalian 
target of rapamycin (mTOR) to affect cell growth (adapted from Shoushtari et al [171]). 
As a result, recent efforts in the understanding of the biology of UM have outlined 
therapies that target mutant G-protein signalling [42]. In this regard, targeted therapies 
in the form of kinase inhibitors that diminish the activity of MEK or PKC in UM patients 
with metastatic disease might be relevant. In a randomised open-label phase 2 study, 
101 metastatic UM patients received the MEK inhibitor selumetinib alone or 
chemotherapy (temozolomide or DTIC); 14% of patients treated with MEK inhibitor 
had an objective radiographic response (either partial or complete response), 
whereas there was no response with chemotherapy alone [172]. Unfortunately, 
almost all patients treated with selumetinib had treatment-related adverse events, with 
37% requiring dose reduction [172]. In this study, selumetinib compared with 
chemotherapy therefore resulted in a modestly improved progression-free survival 
and response rate; however, no improvement in overall survival was observed.  
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Other targeted kinase inhibitors - such as imatinib, sunitinib and sorafenib - are also 
undergoing clinical testing. Both imatinib and sunitinib were used in NCRI-sponsored 
national UK Trials – ITEM and SUAVE, respectively - led by medical oncologists 
based at the Clatterbridge Cancer Centre in Liverpool [173, 174]. Unfortunately, 
neither trial demonstrated any clear benefit. Hence, there is a compelling need for 
effective therapeutic strategies to manage metastatic UM.  
Chen and colleagues demonstrated that chemical inhibition of PKC led to selective 
growth arrest in UM cell lines with GNAQ and GNA11 mutations, and that PKC 
inhibitors can partially or temporarily suppress activation of the MAP-kinase pathway. 
Furthermore, the combination of PKC and MEK inhibitors, synergistically resulted in 
sustained growth inhibition and apoptosis in vitro, and led to tumour regression in a 
mouse model in vivo [175]. In a further study, treatment of GNAQ and GNA11 mutant 
UM cell lines with a combination of the PI3Kα inhibitor BYL719 and PKC inhibitor 
AEB071, showed synergistic inhibition of cell proliferation and apoptotic cell death as 
compared with the effects of either agent alone.  In addition, reduced xenograft tumour 
growth with the combination therapy was demonstrated in a GNAQ mutant mouse 
model [176]. These preclinical findings highlight that a combination of targeted agents 
may improve the outcome of metastatic UM, and also highlight the importance of 
identifying novel targets in this disease.  
Dysregulated pathways in solid cancers commonly involve c-MYC located on 
chromosome 8q, which is thought to influence expression of ~15% of the genome 
responsible for cell growth, proliferation and apoptosis [177]. As a result, this 
transcription factor is thought to be an attractive drug target in the majority of cancers. 
However, although the importance of c-MYC in cancer progression is well 
documented, until recently it has been difficult to target this oncogene since the gene 
product is a transcription factor rather than an enzyme or extracellular receptor. 
However, Delmore and colleagues showed that the Bromodomain (BRD) and 
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ExtraTerminal (BET) family of proteins regulate c-Myc expression and function [178]. 
BET proteins such as bromodomain-containing 4 (BRD4) recruit proteins comprising 
macromolecular transcription complexes to speciﬁc chromatin sites. They contain an 
extraterminal domain and tandem bromodomains that recognise acetylated lysine 
residues on histones. BET inhibitors have been shown to block c-MYC expression in 
a variety of cancers, including multiple myeloma [178], medulloblastoma [179], 
neuroblastoma [180] and glioblastoma [181]. In one study, treatment with BET 
inhibitors impaired cutaneous melanoma cell proliferation in vitro and tumour growth 
and metastatic behaviour in vivo [182]. Furthermore, displacement of BET led to the 
downregulation of key cell cycle genes such as c-MYC, accumulation of cyclin-
dependent kinase (CDK) inhibitors (p21 and p27), and subsequent cell cycle arrest.  
JQ1, a chemical protein-protein interaction (PPI) bromodomain inhibitor, binds to the 
BET domain of BET proteins that interacts with acetylated histones and functions 
to silence transcription downstream of c-MYC. This includes c-MYC itself, and BET 
domain inhibitors are therefore able to decrease c-MYC levels in cells [183]. Shao 
and colleagues showed that JQ1 induced cell cycle arrest and decreased cell 
proliferation of Merkel cell carcinoma, an aggressive skin tumour of neuroendocrine 
origin exhibiting c-MYC protein overexpression. Moreover, JQ1 significantly 
attenuated xenograft tumour growth in vivo [184]. As discussed in Chapter 1, high-
risk UM are usually characterised by monosomy 3 and polysomy 8q [185]. Parrella 
and colleagues showed that in a cohort of 43 UMs, 70% had increased MYC 
expression and of these, 43% had amplification of the c-myc gene, 47% had an 
intermediate relative increase in the c-myc copy number  and 10% had a simple gain 
of chromosome 8 [186].  In a recent investigation, Ambrosini and colleagues explored 
the potential therapeutic effect of JQ1 in UM cells. Treating UM cell lines with JQ1 
induced suppression of c-MYC and triggered apoptosis in only a subset of cell lines, 
including those with GNA11/GNAQ mutations [187]. 
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Other targeted kinase inhibitors that affect the cell cycle, include Aurora and Polo-like 
kinases inhibitors; these can also target c-MYC, although the mechanism is unclear. 
One study showed that Small Cell Lung Cancer (SCLC) cells with c-MYC amplification 
are highly susceptible to specific kinase inhibitors targeting the mitotic Aurora and 
Polo-like kinases. Patient-derived SCLC cell lines were highly sensitive to both the 
Aurora B inhibitor AZD1152 (Barasertib) and the Polo-like kinase inhibitor BI2536, 
and these compounds inhibited proliferation at 3 orders of magnitude lower 
concentrations than in non-MYC amplified lines [188]. The Aurora kinases, A, B and 
C play an essential role in mitotic events regulating cell cycle transit from G2 to 
cytokinesis. MLN8237 (Alisertib) is an Aurora kinase A selective inhibitor that has 
shown encouraging anticancer effects in preclinical studies [189], whilst the Aurora 
kinase B inhibitor Barasertib, has been found to be an essential regulator of 
chromosome segregation in mitosis [190]. Polo-like kinase inhibitors, such as the 
advanced phase III inhibitor BI6727 (Volasertib) and the related probe compound 
BI2536 are also potent and selective cell-cycle kinase inhibitors that induce mitotic 
arrest and apoptosis by targeting Polo-like kinases [191]. Importantly, these drugs 
have recently been shown to target bromodomains [192]. Therefore, these inhibitors 
have gained great attention in targeted therapy and as possible anti-cancer drugs.  
The aim of this chapter was to investigate the cellular effects of a panel of 5 UM cell 
lines to four targeted clinical inhibitors (Table 4.1); the specific Aurora A inhibitor 
MLN8237 (Alisertib), the specific Aurora B inhibitor AZD1152 (Barasertib), the dual 
Polo-like kinase inhibitor and bromodomain inhibitor BI6727 (Volasertib) and the 
bromodomain PPI inhibitor JQ1 (and its inactive stereoisomer JQ1-). 
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Table 4.1 Targeted clinical inhibitors and their current status in clinical trials 
Compound Mechanism of action Clinical trials 
Alisertib Aurora kinase A 
inhibitor 
Phase I: Breast cancer, Non-Hodgkin's 
lymphoma 
Phase I/II: Gynaecological cancer, Non-
small cell lung cancer, Solid tumours 
Phase II: B cell lymphoma; Brain cancer; 
Mesothelioma; Prostate cancer; Small cell 
lung cancer 
Phase III: Discontinued but many others 
recruiting 
Barasertib Aurora kinase B 
inhibitor 
Phase I: Acute Myeloid Leukaemia, 
Myeloid Leukaemia, Lymphoma, Solid 
tumours  
Phase II: Acute Myeloid Leukaemia 
Phase III: Acute Myeloid Leukaemia 
Volasertib Polo-like kinase 1 
inhibitors 
Phase I: Chronic myelomonocytic 
leukaemia; Leukaemia; Solid tumours 
Phase II: Myelodysplastic syndromes; Non-
small cell lung cancer; Ovarian cancer 
Phase III: Acute Myeloid Leukaemia 
JQ1 Bromodomain and 
extraterminal domain 
protein inhibitors 
Not currently in clinical trial due to short 
half-life however structurally similar BET 
inhibitors to JQ1; 
Phase I: NUT Midline carcinoma, Acute 
Myeloid Leukaemia, Lymphoma, Multiple 
myeloma, Leukaemia, Multiple Indications 
Cancer, Advanced Cancer, Solid tumours 
Phase II: Multiple Indications Cancer, 
Advanced Cancer, 
Brain and Central Nervous System Tumours, 
Head and Neck Cancer, Lymphoma 
Phase III: Diabetes Mellitus 
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4.2 Materials and Methods 
 
4.2.1 Small molecule inhibitors 
 
Four small molecules were tested: Bromodomain PPI inhibitor JQ1 and its inactive 
isomer JQ1-, Aurora kinase A inhibitor Alisertib (MLN8237), Aurora kinase B inhibitor 
Barasertib (AZD1152) and Polo-like kinase inhibitor Volasertib (BI6727). The 
inhibitors were kindly provided by Dr Patrick Eyers (University of Liverpool, UK) and 
diluted from a stock concentration of 10 mM in DMSO. Each experiment / assay was 
repeated three times.  
4.2.2 Cell culture 
 
The UM cell lines 92.1, OMM1, OMM2.5, MEL270 and MM66 were cultured as 
described in Chapter 2. Each cell line was harvested by standard trypsin procedures, 
using 0.05% trypsin after cells reached 70% confluence, prior to use in the assay 
described below. 
4.2.3 Sulforhodamine B (SRB) assay 
  
Cells were plated in 96 well plates at 6,250 cells/cm2 (92.1) and 12,500 cells/cm2 
(OMM1, OMM2.5, MEL270 and MM66), using a multi-pipette, in 100 µl of UM medium 
A.  One plate was fixed at 24 hours, and after 72 hours the appropriate kinase or 
BRD4 inhibitors were added at varying concentrations to the appropriate wells. 
Following addition of medium alone or the compounds, plates were fixed every 24 
hours by removing the cell culture medium and adding 100 µl 10% trichloroacetic acid 
(TCA) (10 g TCA flakes/crystals (FisherScientific, UK) in 100 ml H2O) to each well for 
1 hour at 4 ºC. The TCA solution was removed and the plate washed gently with tap 
water and left to air dry.  To visualise cells, 50 µl of Sulforhodamine B (SRB, Sigma) 
solution (0.4% in 1% acetic acid) was added to each well and the plate incubated for 
30 minutes at room temperature. Excess SRB was removed and wells washed with 
1% acetic acid until all unincorporated dye had been removed. Plates were air dried 
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and the incorporated SRB was solubilised in 100 µl 10 mM Tris Base (pH 8.8). The 
absorbance was measured at a wavelength of 565 nm and background absorbance 
at 690 nm, measured using a POLARstar Omega plate reader (BMG Labtech, 
Aylesbury, UK).  
4.2.4 Western blotting 
 
4.2.4.1 Preparation of whole cell lysates 
 
92.1 and OMM1 cells were plated at 6,250 cells/cm2 and 12,500 cells/cm2 respectively 
in 10 cm Petri dishes and cultured for 3 days in medium A. On day 3, 92.1 cells were 
treated with either 220 nM JQ1 (the EC50 concentration established in 92.1 cells) or 1 
µM JQ1 and OMM1 cells with 1 µM JQ1. Both JQ1- and DMSO were included as 
experimental controls. At 24, 48, 72, 96 and 120 hours post addition of compounds, 
cells were washed once with cold PBS and lysed with 300 µl of lysis buffer (1% SDS, 
125 mM Tris pH6.8, 5 mM EDTA, and 10% glycerol). Lysates were kept on ice for 30 
minutes then scraped from the Petri dish using a cell scraper into a microfuge tube. 
The lysates were then sonicated for 30 seconds at 40% power setting and then heated 
at 95 ºC for 10 minutes. Lysates were centrifuged at 12,000 rpm for 10 minutes, and 
the supernatant was transferred to a clean microfuge tube for storage at -20 ºC until 
further use. 
4.2.4.2 Protein determination 
 
The protein concentration in lysates was determined using a Bio-Rad DC protein 
assay kit (Bio-Rad laboratories Ltd, Hertfordshire UK). In brief, a serial dilution of BSA 
standard (0-2 mg/ml) prepared in SDS lysis buffer was added to wells in a 96 well 
plate. In separate wells, 5 µl of cell lysate was pipetted. 1 ml of reagent A was mixed 
with 20 µl of reagent S and 25 µl of this mixture was added to all wells. Finally, 200 µl 
of reagent B was added to all wells and the plate was incubated in the dark for 15 
minutes at room temperature. Absorbance readings were taken at 650 nm, and 
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protein concentration within the samples was determined by comparison with a 
standard curve prepared with BSA protein standards. Measurements were 
considered valid if there was a linear doubling of absorbance with each doubling of 
protein standard concentration, and the correlation coefficient value for the standard 
curve was 0.99. 
For SDS-PAGE, 10 µg of cell lysates were loaded per well. The volume of each 
sample applied was equalised with SDS lysis buffer, and then 5X loading sample 
buffer (5% SDS, 625 mM Tris pH6.8, and 50% glycerol, β- mercaptoethanol and 
bromophenol blue) was added prior to boiling and gel loading. 
4.2.4.3 SDS PolyAcrylamide Gel Electrophoresis (SDS–PAGE) and western 
blotting 
 
Acrylamide gels (10% Running/Resolving and 5% Stacking gels) (Appendix 8) were 
used to separate proteins in lysates. In general, 10 µg of total protein was loaded per 
lane of gel. The Full-Range Rainbow Molecular Weight Marker (GE Healthcare Life 
Sciences, UK) was also loaded for assessing the molecular weight. Membranes were 
blocked with the blocking buffer (5% milk in TBS-T (150 mM NaCl, 25 mM Tris pH 
7.5, 0.1% Tween 20)) for an hour to reduce non-specific binding between the 
membranes and antibodies. 
Membranes were blocked then probed with the primary antibodies, as detailed in 
Table 4.2, then washed and incubated with the appropriate secondary antibody (Table 
4.3). After a final wash, membranes were developed with Immobilon™ Western 
Chemiluminescent HRP substrate (MerckMillipore, Watford, UK), and imaged using 
an LAS-1000 imager (Fujifilm, Japan). Equal protein loading was confirmed by 
probing the blots with anti β-Actin or Histone H3 antibodies (Table 4.3). Different 
loading controls were used to avoid overlap of bands with protein of interest, due to 
the similarities of protein size.   
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Table 4.2. Primary antibodies 
Primary antibody Species Dilution  Supplier 
Monoclonal c-MYC 
 
Rabbit 1:1000 
 
New England Biolabs 
5605 
Monoclonal Histone H3 Rabbit 1:10000 Merck Millipore  
17-10051 
Monoclonal Anti-B-Actin  Mouse 1:10000 Sigma 
A5316 
 
Table 4.3. Secondary antibodies 
Secondary antibody Dilution Supplier 
Goat anti rabbit HRP 1:5000 Santa Cruz Biotechnology 
sc-2004 
Goat anti mouse HRP 1:10000 Santa Cruz Biotechnology 
sc-2031 
 
4.2.5 Cell cycle and apoptosis assay by flow cytometry  
 
Evaluation of cell cycle and apoptotic profiles were performed using a TACS Annexin 
V-FITC Apoptosis Detection Kit (R&D Systems, Abingdon, UK) and analysed on an 
Attune NxT Flow Cytometer (ThermoFisher Scientific, Loughborough, UK).  
4.2.5.1 Preparation of cells  
 
The UM cell lines 92.1 and OMM1 were plated at 6250 cells/cm2 and 12500 cells/cm2 
respectively in 10 cm Petri dishes. At 3, 6, 24, 48, 72, 96 and 120 hours post addition 
of compounds, medium was removed and transferred to a fresh tube. Cells from the 
Petri dishes were harvested with 4 ml of non-enzymatic cell dissociation solution 
(Sigma-Aldrich, UK) and pooled with the medium prior to centrifugation at 300 xg for 
5 minutes at room temperature. The supernatant was discarded and the cell pellet 
was washed in ice cold PBS.  
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4.2.5.2 Cell fixation prior to cycle analysis   
 
Cells were counted, and a minimum of 5 x 105 cells were fixed in 70% ethanol at 4 ºC 
overnight. They were then washed in in PBS and centrifuged at 2000 rpm for 5 
minutes. Cell pellets were re-suspended in 224 µl PBS and 100 ng of RNase A and 
incubated at room temperature for 30 minutes. 25 µl of propidium iodide (PI) solution 
(50 µg/ml) was added prior to analysis on the flow cytometer. At least 20,000 events 
were collected per sample. Data was analysed using Attune NxT Flow Cytometer 
Software. Forward and side-scatter profiles were obtained from the same samples. 
4.2.5.3 Apoptosis 
 
Buffers were prepared according to the instructions provided by the manufacturer. 
Cells were counted and a minimum of 5 x 105 cells were re-suspended in 100 µl 
Annexin V Incubation Reagent followed by the addition of 400 µl 1X Binding Buffer 
and incubated in the dark for 15 minutes. Samples were then analysed on the flow 
cytometer as above.  
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4.3 Results  
 
4.3.1 SRB assay and determination of IC50 
 
An initial experiment was perfomed to examine the effects of a relatively specific 
Aurora A or Aurora B kinase inhibitors, a polo-like kinase inhibitor and a BRD4 
inhibitor on the growth of UM cells. The UM cell lines in exponential growth were 
treated for 72 hours and the cell number examined using the SRB assay. At a 
concentration of 10 µM the Aurora kinase inhibitor, Alisertib (MLN8237) maximally 
reduced cell number of 92.1 cell line by 45%, MEL270 cell line by 42% and OMM1 
cell line by 9%, as compared with untreated control cells (Figure 4.2 A).  
At the same concentration, the Aurora kinase inhibitor, Barasertib (AZD1152) 
maximally reduced cell number of 92.1 cell line by 38%, MEL270 cell line by12%; 
however, had no effect on cell number on the OMM1 cells (Figure 4.2 B). In contrast, 
the effects of the polo-like kinase inhibitor Volasertib (BI6727) and the BRD4 inhibitor 
JQ1 were very much more striking, in terms of effects on cell survival compared with 
untreated controls. Indeed, Volasertib reduced cell number in the 92.1 and MEL270 
cell lines by up to 84% at a concentration of 1 µM, but was less effective in the OMM1 
cell line, requiring a 10-fold higher concentration to reduce cell numbers to similar 
levels (Figure 4.2 C). JQ1 at 1 µM was also more effective in the 92.1 and MEL270 
cell lines when compared with the OMM1 cells reducing the cell numbers by 78%, 
48% and 38%, respectively (Figure 4.3 A). JQ1 was then subsequently tested on an 
additional two UM cell lines: OMM2.5 and MM66 (Figure 4.3 B). 
The concentration of JQ1 that reduced cell number by 50% (IC50) was then 
determined by plotting the values on a log scale (Figure 4.4). The EC50 of 92.1 cells 
treated with JQ1 was 220 nM, which is almost five times lower than that of the MEL270 
cell line, which exhibited an IC50 of 1 µM. OMM1 and MM66 both harbour GNA11 
mutations, compared to the GNAQ mutant cell lines 92.1, MEL270 and OMM2.5, and 
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were the least sensitive to JQ1. Indeed, it was not possible to calculate the IC50 over 
the range of JQ1 concentrations tested for these cells. 
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Figure 4.2. Effect of small molecule inhibitors on the growth of UM cell lines.  Three UM cell lines, 92.1, MEL270 and OMM1 were examined for the effects 
of A. Aurora A inhibitor Alisertib (MLN8237), B. Aurora B inhibitor Barasertib (AZD1152) and C. the polo-like kinase inhibitor Volasertib (BI6727) on cell number. 
Cell lines were exposed to 10-fold serial dilutions over the indicated range. Cell number was quantified using an SRB assay. Bars represent cell number after 
72 hours of continuous exposure as compared with DMSO treated control cells. Data are mean ± SEM of 5 technical replicates in a single experiment. 
A 
B 
C 
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Figure 4.3. Effect of small molecule inhibitor on the growth of UM cell lines. A 92.1, MEL270 and OMM1 cell lines and B. OMM2.5 and MM66 cell lines. 
UM cell lines were employed to establish cell numbers after exposure to JQ1 and JQ1-. The cell lines were exposed to 10-fold serial dilutions over the indicated 
range of the BRD4 PPI inhibitors JQ1 and the inactive stereoisomer JQ1-. Cell number was quantified using an SRB assay. Bars represent cell number after 72 
hours of continuous exposure as compared with DMSO treated control cells. Data points are mean ± SEM of 5 technical replicates in a single experiment. 
A 
B 
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Figure 4.4. Determination of IC50 values for JQ1 in UM cell lines. 92.1, MEL270, OMM2.5, OMM1 and MM66 cell lines were exposed to 10-fold serial dilutions 
of JQ1. IC50 values calculated 72 hours after continuous exposure. Cell number was normalised to DMSO-treated cells. Error bars too small to see. 
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4.3.2 c-MYC protein expression levels following treatment of JQ1 
 
Based on the presence of c-MYC gene amplification in UM and the previously 
reported inhibitory effects of JQ1 on c-MYC protein levels, c-MYC protein was 
examined following treatment of two of the UM cell lines, 92.1 (GNAQ mutant) and 
OMM1 (GNA11 mutant) with JQ1. To evaluate c-MYC expression, whole cell lysates 
were prepared at multiple 24-hour intervals following the addition of JQ1. At the IC50 
concentration of JQ1 (220 nM), c-MYC protein expression was reduced compared 
with controls in the 92.1 UM cell line. This was seen from 24 hours following 
compound exposure, and maintained over 72 hours (Figure 4.5 A). The effect was 
also observed at 1 µM JQ1 in the 92.1 UM cell line at 72 hours following treatment 
(Figure 4.5 B). However, this effect was not observed with OMM1 cells, where c-MYC 
barely changed after treatment with 1 µM JQ1 for 24 and 48 hours, and actually 
increased between 72 and 120 hours after exposure (Figure 4.6). 
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Figure 4.5. JQ1 down-regulates c-MYC expression in 92.1 cells. A. 92.1 cell line was 
exposed to the IC50 concentration of JQ1 (220 nM). Cell lysates were analysed for c-MYC 
expression and β-actin was used as a loading control, at the indicated time-points after 
compound addition by western blotting. Respective densitometry also shown. B. Cells were 
exposed to 1 µM JQ1 for 72 hours and processed as in A. Respective densitometry also 
shown. 
A 
B 
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Figure 4.6. Effect of JQ1 on c-MYC expression in OMM1 cells. OMM1 cell line was exposed 
to 1 µM JQ1. Cell lysates were analysed for c-MYC expression and β-actin was used as a 
loading control, at the indicated time-points after compound addition by western blotting. 
Respective densitometry also shown. 
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4.3.3 Effect of JQ1 on cell cycle profile and apoptosis 
  
Downregulation of c-MYC has previously been associated with cell cycle arrest  [193]. 
To investigate the possibility that the JQ1-induced reduction of c-MYC protein levels 
was also associated with cell cycle arrest, cell cycle profiles (flow cytometry) and 
western blotting of cyclin D1 levels were examined. 92.1 cells treated with 220 nM 
JQ1 showed a decrease in the number of cells in S phase with a concomitant increase 
in cell numbers in G0 / G1 phase as compared with both mock DMSO, JQ1- treated 
negative control cells. At 24 hours after treatment of 92.1 cells with JQ1, 86% were in 
G1 phase with only 2% in S phase, compared to 55% and 64% in G1 phase in cells 
treated with DMSO and JQ1- negative controls respectively, with approximately 20% 
of cells in S phase in both controls. The G0 / G1 cell cycle arrest was maintained for 
up to 120 hours following treatment with 220 nM JQ1 (Figure 4.7). A similar G0 / G1 
cell cycle arrest was also seen when 92.1 cells were treated at the higher 
concentration of 1 µM JQ1 over a period of 72 hours (Figure 4.8). Similar results were 
also obtained with OMM1 cells treated with 1 µM JQ1, with a decrease of cells in S 
phase and accumulation of cells in the G0 / G1 phase of the cells cycle. At 24 hours 
after treatment of OMM1 cells with JQ1, 56% were in G1 phase and 6% in S phase 
compared to DMSO and JQ1- treated negative controls, which showed 48% and 44% 
in G1 phase and 10% and 15% in S phase respectively. An increase of OMM1 cells 
in G0 / G1 phase of the cell cycle was maintained up to 120 hours with 86% in G1 
and only 2% in S phase compared to 54% and 64% in G1 phase and 20% and 23% 
in S phase with mock DMSO and JQ1- treated negative control cells (Figure 4.9).  
Further assessment of the effects of JQ1 on cell cycle progression was performed by 
examining cyclin D1 protein levels by western blotting. Cyclin D1 synthesis is required 
for G1 / S phase transition and accumulates during G1 before being degraded as the 
cells enter S phase [194]. Upregulation of Cyclin D1 was detected in both 92.1 and 
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OMM1 cell lines treated with 220 nM and 1 µM JQ1, respectively (Figure 4.10 A and 
B).  
To further understand the mechanism by which JQ1 reduces UM cell number, effects 
on apoptosis in exposed cells was also evaluated. At the IC50 dose, JQ1 failed to 
induce apoptosis in 92.1 cells, as demonstrated by the Annexin V assay (Figure 4.11). 
However at the higher concentration of 1 µM JQ1, initiation of apoptosis was detected 
at 24 hours and this was maintained for up to 72 hours (Figure 4.12). JQ1 at 1 µM 
failed to induce apoptosis in OMM1 cells (Figure 4.13). These results were further 
investigated by western blotting with caspase 3, since caspase 3 is one of the 
executioner caspases activated by proteolytic cleavage during apoptosis. Only 
uncleaved caspase 3 was observed in the western blots, with no indication of cleaved 
caspase 3 as a result of apoptosis following treatment with 1 µM JQ1 in either 92.1 or 
OMM1 cell lines (Figure 4.15 and 4.16). As a control, exposure of both 92.1 and 
OMM1 cells with 1 µM Staurosporine for 16 hours induced caspase 3 cleavage 
(Figure 4.14). 
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Figure 4.7. Effect of JQ1 on 92.1 cell cycle profile. 92.1 cells were exposed to JQ1 for the 
indicated times (24 – 120 hours). DNA was stained with PI and the cell cycle distribution was 
analysed by flow cytometry. A. Percentage of cells treated with 220 nM JQ1 in G1, S and 
G2/M phases are indicated in a representative plot at 48 hours. DNA content was compared 
to DMSO controls and JQ1-.  B. Cells treated with 220 nM and C. 1 µM JQ1.  
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Figure 4.8. Effect of JQ1 on OMM1 cell cycle profile. OMM1 cells were exposed to JQ1 for 
the indicated times (24 – 120 hours). DNA was stained with PI and the cell cycle distribution 
was analysed by flow cytometry. A. Percentage of cells treated with 220 nM JQ1 in G1, S and 
G2/M phases are indicated in a representative plot at 48 hours. DNA content was compared 
to DMSO controls and JQ1-.  B. Cells treated with 1 µM JQ1.  
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Figure 4.9. JQ1 up-regulates Cyclin D1 expression levels in 92.1 and OMM1 cells. A. 
92.1 cells exposed to the EC50 of JQ1 (220 nM) established previously. Cell lysates were 
analysed for Cyclin D1 levels and Histone H3 was employed as a loading control. B. OMM1 
cells were exposed to 1 µM JQ1. Cell lysates were analysed for Cyclin D1 levels and β-actin 
was used as a loading control. 
A 
B 
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Figure 4.10. Effect of JQ1 on apoptosis in 92.1 cells. A. Analysis of apoptosis by Annexin-
V and propidium iodide (PI) double-staining flow cytometry after treatment with 220 nM JQ1, 
demonstrated in a representative plot at 48 hours. B. Percentage of live cells treated with 220 
nM JQ1 and C. 1 µM JQ1. 
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Figure 4.11. Effect of JQ1 on OMM1 cell apoptosis. A. Analysis of apoptosis by Annexin-V 
and propidium iodide (PI) double-staining flow cytometry after treatment with 1 µM JQ1, 
demonstrated in a representative plot at 48 hours. B. Percentage of live cells treated with 1 
µM JQ1.
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Figure 4.12. Staurosporine causes apoptosis in OMM1 cells and 92.1 cells. Cells were treated 
with 1µM Staurosporine for 16 hours. 
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Figure 4.15. Western blot analysis of Caspase 3 in 92.1 cell line. A. 92.1 cells were treated 
with 1 µM Staurosporine for 16 hours. B. 92.1 cells were treated with 1 μM JQ1 at the indicated 
time points, and lysates subjected to western blot analysis with the indicated antibodies. Note 
the reduction in total actin and Caspase 3 in 48 hour JQ1 time-point, which may mask effects 
on cleavage of Caspase 3 
B 
A 
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Figure 4.16. Western blot analysis of Caspase 3 in OMM1 cell line. A.  OMM1 cells were 
treated with 1 µM Staurosporine for 16 hours. B. OMM1 cells were treated with 1 μM JQ1 at 
the indicated time points, and lysates subjected to western blot analysis with the indicated 
antibodies. 
B 
A 
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4.4 Discussion 
 
Previous studies have demonstrated that extra copies of MYC are present in UM [21, 
186, 195]. PCR analysis of 600 UM patient samples obtained for prognosis purposes 
(1998 – 2012) demonstrated amplified MYC gene levels in 252 out of the 600 cases 
(42%). Of these, 155 were also classified as monosomy 3 and survival time of ‘high 
risk’ monosomy 3 UM patients is significantly reduced if MYC amplification is also 
present [21]. Unpublished data from MLPA analysis also demonstrated MYC 
amplification in 92.1 cell line, in contrast to the MEL270 cell line. As a result, it has 
been proposed that MYC status represents a novel therapeutic target in a high 
percentage of 8q-amplified UMs. However, when verifying this with a western blot, 
there were no obvious differences observed between the c-MYC expression levels of 
92.1 and MEL270 cell lines, at least at the protein level. Despite this, interesting 
results were obtained when the 5 UM cell lines in this study were exposed to a panel 
of targeted clinical inhibitors that have significant potential for the treatment of human 
cancer. 
Although the Aurora kinase inhibitors did not significantly affect cell number in the UM 
cell lines here, the Polo-like kinase inhibitor Volasertib and the Bromodomain inhibitor 
JQ1 reduced 92.1 cell numbers by 84% and 78% respectively (Figure 4.3). Since JQ1 
was the most potent drug, and to assess whether a correlation could be confirmed 
between JQ1 sensitivity and GNA11 and GNAQ mutational status, a further two cell 
lines OMM2.5 (GNAQ mutant) and MM66 (GNA11 mutant) were evaluated (Figure 
4.2). Interestingly, OMM1 and MM66 cell lines, which harbour a GNA11 mutation, 
were the least sensitive to JQ1, so that an EC50 for each cell line at the range of tested 
concentrations could not be calculated (Figure 4.4). The other sensitive cell lines 
tested, including the MEL270 and OMM2.5 cell lines, all harbour GNAQ mutations, 
and are from the same patient as described in Chapter 2. This highlights the 
importance of different genetic mutations between cell lines and patients, as it shows 
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how one patient may be less sensitive to a treatment than another based on these 
mutations. As a result tailoring therapies depending on patients' genetic make-up and 
molecular profiling are important for targeted therapies and patient stratification. The 
discovery of key mutations in UM such as GNAQ / GNA11, have resulted in significant 
investigations in the MEK and PKC signalling pathways and consequently in 
MEK/PKC inhibitors. However, MEK and PKC inhibitors as single target agents have 
failed to improve overall survival in comparison to chemotherapy; in combination, on 
the other hand, they have shown promising results, as discussed earlier in this 
Chapter [175]. Therefore, multiple targeted agents used in combination may be 
required to effectively treat metastatic UM.  
Members of the MYC family of proteins are commonly mutated or amplified in 
cancers, however it has traditionally been very challenging to target these and to 
develop drugs that inhibit this transcription factor. Fortunately, experimental BET-
domain inhibitors, such as JQ1, have been established as the first of a family of new 
drugs that inhibit effects of this oncogenic transcription factor and in UM, inhibit tumour 
progression in vitro and also in vivo [187]. This is consistent with the findings in this 
Chapter with JQ1 exposure in 92.1 cell line; however, similar effects were not 
observed in the OMM1 cell line, in fact an increase in c-MYC levels was seen between 
72 and 120 hours following treatment. This could perhaps be due to underlying 
genetic differences between both cell lines, such as the GNAQ / GNA11 mutations 
and further cell cycle related proteins. Previous studies have reported alterations in 
cyclin D1 and related cell-cycle proteins in UM cell lines [196] and UM tissue samples 
[197]. The latter study, analysed 96 eyes enucleated for UM immunohistochemically 
for the protein expression of cyclin D1 and related cell-cycle markers. Cyclin D1 
positivity (>15% positive tumour cells) was associated with an unfavourable outcome 
(death from metastasis within the first 5 years). In addition, cyclin D1 positivity was 
associated with the presence of extraocular melanoma extension, and with the mixed 
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or epithelioid cell type; therefore, the overexpression of cyclin D1 in UM is associated 
with a more aggressive course and histologically unfavourable disease [197]. In this 
investigation, cyclin D1 levels increased in 92.1 and OMM1 cell lines treated with JQ1, 
consistent with the cell cycle arrest data in this Chapter.  
BET inhibitors have been shown to have cytostatic effects in several tumour types, 
and when used in combination with other drugs, they can induce synergistic effects 
[198]. Boi and colleagues assessed the preclinical activity of the BET bromodomain 
inhibitor OTX015 as single agent and in combination in mature B-cell lymphoma 
models. OTX015 effect was largely cytostatic, with induction of apoptosis in only a 
genetically defined subset of cell lines, it also inhibits MYC pathway. Furthermore, it 
shows synergistic or additive effects when combined with several anti-lymphoma 
agents. Therefore, as mentioned previously, it is likely that multiple targeted agents 
should be used in combination to effectively treat metastatic disease. It is thought that 
the GNAQ/GNA11 mutations are initiating events in UM pathogenesis, as discussed 
in Chapter 1, and additional mutations, such as inactivating mutations in BAP1 
(located on chromosome 3) are required for metastasis. As a result, HDACi are 
leading candidates for combination therapy since treatment of UM cells with these 
inhibitors have shown reduced tumour growth by inducing cell-cycle exit, and a shift 
to a differentiated, melanocytic gene expression profile [34]. It will be interesting to 
assess the effects of HDACi on the UM cells employed in this thesis. However, JQ1 
independently caused cell cycle arrest in both 92.1 and OMM1 cell lines and as a 
result, drug combinations may not be necessary for the treatment of some UMs. This 
was highlighted by Ambrosini and colleagues who showed that combination of JQ1 
with other small molecules targeting mutant GNAQ signalling did not have a 
synergistic effect [187]. 
Further investigations are required to better understand the effects of these 
compounds on UM cell lines. For example, do the treated UM cells remain in cell cycle 
111 
 
arrest, or do they eventually re-enter the cell cycle and if so, would this pattern be 
repeated with further application of the compounds. Furthermore, it is unclear why 
only a slight initiation in apoptosis was seen in 92.1 UM cells treated with JQ1 with no 
evidence of cleavage of caspase 3, similarly with OMM1 cells. Also of interest for 
future investigations is Volasertib (BI6727) which, as well as a kinase inhibitor, also 
targets bromodomains thus acting as a “dual-targeted single agent” [192]. Therefore 
this compound could potentially offer the same benefits as combination therapies 
whilst minimising some of the toxic liabilities of combination approaches. Due to time 
constraints and the necessity to first establish and optimise the baseline assays and 
drug concentrations, these assays were not conducted in our 3D model. However, 
these investigations can further be applied to more representative in vitro and in vivo 
environments established in this thesis; the compounds can be applied to tumour 
spheroids where their effect can be observed in a 3D tumour setting outlined in 
Chapter 2, and further to the chick embryo model system in an in vivo environment 
outlined in Chapter 3. These representative settings will further pave the way for the 
application of potential clinical trials.   
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Chapter 5 
Conclusions and future perspectives 
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Advances in the treatment of primary UM have been successful in achieving local 
tumour control rates of approximately 95%; however metastatic UM remains fatal due 
to ineffective therapies. Most UM patients who develop liver metastases therefore 
have a very poor prognosis. The development of in vitro and in vivo models can 
provide the necessary tools to better understand disseminated UM, and as pre-clinical 
models for drug testing.  
The scope of this thesis was to develop and characterise in vitro and in vivo models 
for the study of UM and its metastases that may be used in preclinical testing. In 
Chapter 2, the ability to grow and characterise in vitro 3D tumour spheroids from 
patient derived UM samples was described. Attempts with the established UM cell 
lines to form tumour spheroids proved difficult as they failed to form compact tumour 
spheroids that were easy to handle. Furthermore, although from the original patient 
tumour, most established UM cell lines used in studies are limited, since these cell 
lines have lost many of their original characteristics during repeated passages in 
culture [199].  In addition, the complexity of cell growth in its in vivo environment is far 
beyond that achieved in 2D culture. 3D spheroid culture using cells isolated from 
patient tumours is a step towards creating a more representative environment. 
Chapter 2 demonstrated for the first time that 3D tumour spheroids can be 
successfully established from UM patient samples in a relatively short timescale and 
that they retain many morphological and molecular characteristics of the original 
tumour. For example, the presence of macrophages, a key feature of UM associated 
with a poorer prognosis, was retained in the tumour spheroids. 
 Indeed, some of the primary tumour cells failed to form tumour spheroids, however 
experiments including co-culture experiments to assess the behaviour of the tumour 
cells with other cells found in their natural environment, such as endothelial cells and 
/ or hepatic cells to mimic the metastatic niche may further enhance the tumour 
spheroid efficiency and the relevance of these models for pre-clinical testing. In 
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addition, further studies with a larger panel of tumour cells can provide further insight 
into determining key mutations and genes that can affect the tumour formation 
efficiency and what parameters influence spheroid formation. Further investigations 
of this model as a simple, high throughput method for drug testing and screening 
warrants investigation and may pave the way to personalised medicine for UM 
patients. Furthermore, since tumours are enriched with a blood supply in their natural 
environment, future experiments can recapitulate this by transferring the tumour 
spheroids to an in vivo model. 
In Chapter 3, an in vivo chick embryo model is described in which not only UM tumour 
cell morphology, behaviour and migration can be assessed but also with which 
spontaneous metastasis can be investigated. The majority of animal models are 
costly, difficult to maintain and time consuming. Currently, there are no representative 
models of UM; this chapter has presented a cost-effective, efficient and simple chick 
embryo model with which results can be obtained in a short period of time. A panel of 
UM cell lines that represent the characteristic genetic and morphological profile in UM 
were used. Intravenous injections in this model showed homing of the cells to the 
uveal tract and the liver in a similar manner to UM cells in a patient. Furthermore, the 
ease of access of this model allowed for a platform, the CAM, for tumour nodule 
formation. Although these experiments were successfully achieved, certain limitations 
still remain and future experiments are required to improve this model beyond the 
initial baseline steps achieved here. For example, spontaneous metastasis was not 
observed in this model, and there are a substantial number of cells found in organs 
other than those of interest after intravenous injections of tumour cells. Further studies 
such as culturing cells in hypoxia and using primary UM cells may lead to 
spontaneous metastasis demonstrated for other tumours in this model [157]. In 
addition, longer incubation of the embryos, could determine whether cells found in 
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other organs would survive. This platform can be further used as an in vivo 
environment to treat these tumour nodules with potential therapeutic drugs. 
Although the aims of Chapter 2 and 3 were to optimise the in vitro and in vivo 
environments, in order to better understand the processes involved in UM metastasis 
it is clear that one of the ultimate goals is to establish a preclinical setting in which 
therapeutic agents can be applied with the aim that they are introduced into clinical 
trials. Chapter 4 investigated the effects of four targeted clinical inhibitors on UM cell 
lines. In two UM cell lines, 92.1 and OMM1, JQ1 independently caused cell cycle 
arrest. Another inhibitor, Volasertib, also showed promising results, however due to 
time constraints was not examined further. Due to its “dual-targeted single agent” 
nature discussed in Chapter 4, it would be of great interest to examine its effects 
further in similar experiments to those performed with JQ1 in this Chapter. The 
promising results achieved with JQ1 paved the way for many insightful investigations 
and experiments. Further investigations are required to elaborate on the results 
achieved in this Chapter; for example, it is unclear why JQ1 causes apoptosis in both 
92.1 and OMM1 UM cell lines but does not lead to cleavage of caspase 3, would this 
effect be observed in additional cell lines and if so, could this be as a result of the 
different genetic mutations commonly found in UM e.g. GNA11/GNAQ. Therefore, 
these experiments need to be carried out with a larger panel of cell lines that are also 
representative of common alterations and mutations in UM. For example, the cell lines 
used in this investigation did not harbour BAP1 mutations, found in majority of 
metastasising UM, would these cells behave differently or respond at all, if exposed 
to the drugs. Furthermore, would the 3D tumour spheroids respond in a similar 
manner to the cell lines exposed to the drugs in 2D or would they be less / more 
sensitive or perhaps show no response at all. There is now also accumulating 
evidence indicating that cell death can occur in a programmed fashion but in complete 
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absence and independent of caspase activation, therefore, the absence of cleavage 
of caspase 3 seen here, could also be due to caspase-independent cell death [200]. 
The 3D tumour spheroids established in Chapter 2 are an ideal next step in assessing 
the drugs as the 3D environment provides a representative setting that closely 
represents a solid tumour. A further established environment in Chapter 3, the chick 
embryo, is an ideal in vivo environment with which to assess the effects of these 
compounds. For example, tumour spheroids can be directly placed onto the CAM and 
after a period of time when they have recruited blood vessels and adapted to the in 
vivo environment, the compounds can be administered. This can establish a 
representative in vivo setting for pre-clinical drug testing.   
Steps such as those uncovered in this thesis can facilitate preclinical analysis of new 
anticancer compounds against metastatic UM for each UM patient in a time- and cost-
effective manner. 
 
 
 
 
117 
 
 
Bibliography 
 
1. Kashyap, S., et al., Uveal melanoma. Semin Diagn Pathol, 2016. 
2. Egan, K.M., et al., Epidemiologic aspects of uveal melanoma. Surv Ophthalmol, 1988. 
32(4): p. 239-51. 
3. Seddon, J.M., et al., Host factors, UV radiation, and risk of uveal melanoma. A case-
control study. Arch Ophthalmol, 1990. 108(9): p. 1274-80. 
4. van Hees, C.L., et al., Are atypical nevi a risk factor for uveal melanoma? A case-
control study. J Invest Dermatol, 1994. 103(2): p. 202-5. 
5. Ewens, K.G., et al., Genomic profile of 320 uveal melanoma cases: chromosome 8p-
loss and metastatic outcome. Invest Ophthalmol Vis Sci, 2013. 54(8): p. 5721-9. 
6. Singh, A.D., et al., Uveal melanoma in young patients. Arch Ophthalmol, 2000. 118(7): 
p. 918-23. 
7. Damato, B.E. and S.E. Coupland, Differences in uveal melanomas between men and 
women from the British Isles. Eye (Lond), 2012. 26(2): p. 292-9. 
8. Singh, A.D., et al., Familial uveal melanoma. Clinical observations on 56 patients. Arch 
Ophthalmol, 1996. 114(4): p. 392-9. 
9. van Beek, J.G.M., et al., Diagnosis, Histopathologic and Genetic Classification of Uveal 
Melanoma. 2013: INTECH Open Access Publisher. 
10. Damato, B. and H. Heimann, Personalized treatment of uveal melanoma. Eye (Lond), 
2013. 27(2): p. 172-9. 
11. Damato, B., et al., Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol 
Phys, 2005. 63(1): p. 109-15. 
12. Shields, C.L., et al., Radiation therapy for uveal malignant melanoma. Ophthalmic 
Surg Lasers, 1998. 29(5): p. 397-409. 
13. Mashayekhi, A., et al., Primary transpupillary thermotherapy for choroidal melanoma 
in 391 cases: importance of risk factors in tumor control. Ophthalmology, 2015. 
122(3): p. 600-9. 
14. Damato, B., et al., Artificial neural networks estimating survival probability after 
treatment of choroidal melanoma. Ophthalmology, 2008. 115(9): p. 1598-607. 
15. Damato, B., et al., Estimating prognosis for survival after treatment of choroidal 
melanoma. Prog Retin Eye Res, 2011. 30(5): p. 285-95. 
16. Damato, B., et al., Cytogenetics of uveal melanoma: a 7-year clinical experience. 
Ophthalmology, 2007. 114(10): p. 1925-31. 
17. Toivonen, P., et al., Microcirculation and tumor-infiltrating macrophages in choroidal 
and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci, 
2004. 45(1): p. 1-6. 
18. Ksander, B.R., et al., Uveal melanomas contain antigenically specific and non-specific 
infiltrating lymphocytes. Curr Eye Res, 1998. 17(2): p. 165-73. 
19. Prescher, G., et al., Prognostic implications of monosomy 3 in uveal melanoma. 
Lancet, 1996. 347(9010): p. 1222-5. 
20. Coupland, S.E., et al., Molecular pathology of uveal melanoma. Eye (Lond), 2013. 
27(2): p. 230-42. 
21. Caines, R., et al., Cluster analysis of multiplex ligation-dependent probe amplification 
data in choroidal melanoma. Mol Vis, 2015. 21: p. 1-11. 
22. McCarthy, C., et al., Insights into genetic alterations of liver metastases from uveal 
melanoma. Pigment Cell Melanoma Res, 2016. 29(1): p. 60-7. 
118 
 
23. White, V.A., et al., Correlation of cytogenetic abnormalities with the outcome of 
patients with uveal melanoma. Cancer, 1998. 83(2): p. 354-9. 
24. Damato, B., J.A. Dopierala, and S.E. Coupland, Genotypic profiling of 452 choroidal 
melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res, 
2010. 16(24): p. 6083-92. 
25. Van Raamsdonk, C.D., et al., Frequent somatic mutations of GNAQ in uveal melanoma 
and blue naevi. Nature, 2009. 457(7229): p. 599-602. 
26. Luke, J.J., et al., Biology of advanced uveal melanoma and next steps for clinical 
therapeutics. Pigment Cell Melanoma Res, 2015. 28(2): p. 135-47. 
27. Griewank, K.G. and R. Murali, Pathology and genetics of uveal melanoma. Pathology, 
2013. 45(1): p. 18-27. 
28. Harbour, J.W., et al., Frequent mutation of BAP1 in metastasizing uveal melanomas. 
Science, 2010. 330(6009): p. 1410-3. 
29. Farmer, H., et al., Targeting the DNA repair defect in BRCA mutant cells as a 
therapeutic strategy. Nature, 2005. 434(7035): p. 917-21. 
30. Koopmans, A.E., et al., Clinical significance of immunohistochemistry for detection of 
BAP1 mutations in uveal melanoma. Mod Pathol, 2014. 27(10): p. 1321-30. 
31. Kalirai, H., et al., Lack of BAP1 protein expression in uveal melanoma is associated 
with increased metastatic risk and has utility in routine prognostic testing. Br J 
Cancer, 2014. 111(7): p. 1373-80. 
32. Matatall, K.A., et al., BAP1 deficiency causes loss of melanocytic cell identity in uveal 
melanoma. BMC Cancer, 2013. 13: p. 371. 
33. Abdel-Rahman, M.H., et al., Germline BAP1 mutation predisposes to uveal 
melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet, 
2011. 48(12): p. 856-9. 
34. Landreville, S., et al., Histone deacetylase inhibitors induce growth arrest and 
differentiation in uveal melanoma. Clin Cancer Res, 2012. 18(2): p. 408-16. 
35. Harbour, J.W., et al., Recurrent mutations at codon 625 of the splicing factor SF3B1 
in uveal melanoma. Nat Genet, 2013. 45(2): p. 133-5. 
36. Griewank, K.G., et al., Genetic and clinico-pathologic analysis of metastatic uveal 
melanoma. Mod Pathol, 2014. 27(2): p. 175-83. 
37. Furney, S.J., et al., SF3B1 mutations are associated with alternative splicing in uveal 
melanoma. Cancer Discov, 2013. 3(10): p. 1122-9. 
38. Johansson, P., et al., Deep sequencing of uveal melanoma identifies a recurrent 
mutation in PLCB4. Oncotarget, 2016. 7(4): p. 4624-31. 
39. Martin, M., et al., Exome sequencing identifies recurrent somatic mutations in EIF1AX 
and SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013. 45(8): p. 933-6. 
40. Eskelin, S., et al., A prognostic model and staging for metastatic uveal melanoma. 
Cancer, 2003. 97(2): p. 465-75. 
41. Augsburger, J.J., Z.M. Correa, and A.H. Shaikh, Effectiveness of treatments for 
metastatic uveal melanoma. Am J Ophthalmol, 2009. 148(1): p. 119-27. 
42. Patel, M., et al., Therapeutic implications of the emerging molecular biology of uveal 
melanoma. Clin Cancer Res, 2011. 17(8): p. 2087-100. 
43. Coupland, S.E., et al., Metastatic choroidal melanoma to the contralateral orbit 40 
years after enucleation. Arch Ophthalmol, 1996. 114(6): p. 751-6. 
44. Blanco, P.L., et al., Uveal melanoma dormancy: an acceptable clinical endpoint? 
Melanoma Res, 2012. 22(5): p. 334-40. 
45. Grossniklaus, H.E., Progression of ocular melanoma metastasis to the liver: the 2012 
Zimmerman lecture, in JAMA Ophthalmol. 2013: United States. p. 462-9. 
46. Dithmar, S., D.M. Albert, and H.E. Grossniklaus, Animal models of uveal melanoma. 
Melanoma Res, 2000. 10(3): p. 195-211. 
119 
 
47. Tolleson, W.H., et al., Spontaneous uveal amelanotic melanoma in transgenic Tyr-
RAS+ Ink4a/Arf-/- mice. Arch Ophthalmol, 2005. 123(8): p. 1088-94. 
48. Ma, D. and J.Y. Niederkorn, Efficacy of tumor-infiltrating lymphocytes in the 
treatment of hepatic metastases arising from transgenic intraocular tumors in mice. 
Invest Ophthalmol Vis Sci, 1995. 36(6): p. 1067-75. 
49. Schiffner, S., et al., Tg(Grm1) transgenic mice: a murine model that mimics 
spontaneous uveal melanoma in humans? Exp Eye Res, 2014. 127: p. 59-68. 
50. Cao, J. and M.J. Jager, Animal Eye Models for Uveal Melanoma. Ocul Oncol Pathol, 
2015. 1(3): p. 141-50. 
51. Greene, H.S., A spontaneous melanoma in the hamster with a propensity for 
amelanotic alteration and sarcomatous transformation during transplantation. 
Cancer Res, 1958. 18(4): p. 422-5. 
52. Journee-de Korver, J.G., et al., Transpupillary thermotherapy (TTT) by infrared 
irradiation of choroidal melanoma. Doc Ophthalmol, 1992. 82(3): p. 185-91. 
53. Journee-de Korver, J.G., J.A. Oosterhuis, and G.F. Vrensen, Light and electron 
microscopic findings on experimental melanomas after hyperthermia at 50 degrees 
C. Melanoma Res, 1995. 5(6): p. 393-402. 
54. Rem, A.I., et al., Transscleral laser thermotherapy of hamster Greene melanoma: 
inducing tumour necrosis without scleral damage. Melanoma Res, 2001. 11(5): p. 
503-9. 
55. Bomirski, A., A. Slominski, and J. Bigda, The natural history of a family of 
transplantable melanomas in hamsters. Cancer Metastasis Rev, 1988. 7(2): p. 95-118. 
56. Urbanska, K., et al., Experimental ruthenium plaque therapy of amelanotic and 
melanotic melanomas in the hamster eye. Melanoma Res, 2000. 10(1): p. 26-35. 
57. Romanowska-Dixon, B., et al., Angiomorphology of the pigmented Bomirski 
melanoma growing in hamster eye. Ann Anat, 2001. 183(6): p. 559-65. 
58. Greene, H.S. and E.K. Harvey, The growth and metastasis of amelanotic melanomas 
in heterologous hosts. Cancer Res, 1966. 26(4): p. 706-14. 
59. Rem, A.I., et al., Transscleral thermotherapy with laser-induced and conductive 
heating in hamster Greene melanoma. Melanoma Res, 2004. 14(5): p. 409-14. 
60. Braun, R.D., et al., Hemodynamic parameters in blood vessels in choroidal melanoma 
xenografts and rat choroid. Invest Ophthalmol Vis Sci, 2002. 43(9): p. 3045-52. 
61. Braun, R.D. and K.S. Vistisen, Modeling human choroidal melanoma xenograft 
growth in immunocompromised rodents to assess treatment efficacy. Invest 
Ophthalmol Vis Sci, 2012. 53(6): p. 2693-701. 
62. Braun, R.D. and A. Abbas, Orthotopic human choroidal melanoma xenografts in nude 
rats with aggressive and nonaggressive PAS staining patterns. Invest Ophthalmol Vis 
Sci, 2006. 47(1): p. 7-16. 
63. Braun, R.D. and K.S. Vistisen, Measurement of human choroidal melanoma xenograft 
volume in rats using high-frequency ultrasound. Invest Ophthalmol Vis Sci, 2008. 
49(1): p. 16-22. 
64. Hill, R.A., et al., Photodynamic therapy of ocular melanoma with bis silicon 2,3-
naphthalocyanine in a rabbit model. Invest Ophthalmol Vis Sci, 1995. 36(12): p. 2476-
81. 
65. Blanco, P.L., et al., Characterization of ocular and metastatic uveal melanoma in an 
animal model. Invest Ophthalmol Vis Sci, 2005. 46(12): p. 4376-82. 
66. Krause, M.H., et al., MRI of blood volume with MS 325 in experimental choroidal 
melanoma. Magn Reson Imaging, 2003. 21(7): p. 725-32. 
67. Krause, M., et al., MRI of blood volume and cellular uptake of superparamagnetic iron 
in an animal model of choroidal melanoma. Ophthalmic Res, 2002. 34(4): p. 241-50. 
120 
 
68. Krause, M.H., et al., Treatment of experimental choroidal melanoma with an 
Nd:yttrium-lanthanum-fluoride laser at 1047 nm. Arch Ophthalmol, 2003. 121(3): p. 
357-63. 
69. Hu, L.K., et al., Establishment of pigmented choroidal melanomas in a rabbit model. 
Retina, 1994. 14(3): p. 264-9. 
70. Mueller, A.J., et al., Evaluation of the human choroidal melanoma rabbit model for 
studying microcirculation patterns with confocal ICG and histology. Exp Eye Res, 
1999. 68(6): p. 671-8. 
71. Blanco, G., et al., Uveal melanoma model with metastasis in rabbits: effects of 
different doses of cyclosporine A. Curr Eye Res, 2000. 21(3): p. 740-7. 
72. Bonicel, P., et al., Establishment of IPC 227 cells as human xenografts in rabbits: a 
model of uveal melanoma. Melanoma Res, 2000. 10(5): p. 445-50. 
73. Lopez-Velasco, R., et al., Efficacy of five human melanocytic cell lines in experimental 
rabbit choroidal melanoma. Melanoma Res, 2005. 15(1): p. 29-37. 
74. Marshall, J.C., et al., The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular 
and metastatic animal model of uveal melanoma. Carcinogenesis, 2007. 28(9): p. 
2053-8. 
75. Marshall, J.C., et al., Transcriptional profiling of human uveal melanoma from cell 
lines to intraocular tumors to metastasis. Clin Exp Metastasis, 2007. 24(5): p. 353-62. 
76. Di Cesare, S., et al., The effect of blue light exposure in an ocular melanoma animal 
model. J Exp Clin Cancer Res, 2009. 28: p. 48. 
77. Kang, S.J., et al., In vivo high-frequency contrast-enhanced ultrasonography of 
choroidal melanoma in rabbits: imaging features and histopathologic correlations. Br 
J Ophthalmol, 2013. 97(7): p. 929-33. 
78. Lambrou, F.H., et al., A new technique for subchoroidal implantation of experimental 
malignant melanoma. Invest Ophthalmol Vis Sci, 1988. 29(6): p. 995-8. 
79. Romer, T.J., et al., Hamster Greene melanoma implanted in the anterior chamber of 
a rabbit eye: a reliable tumor model? Ophthalmic Res, 1992. 24(2): p. 119-24. 
80. De Waard-Siebinga, I., et al., Establishment and characterization of an uveal-
melanoma cell line. Int J Cancer, 1995. 62(2): p. 155-61. 
81. Grossniklaus, H.E., et al., Anterior vs posterior intraocular melanoma. Metastatic 
differences in a murine model. Arch Ophthalmol, 1996. 114(9): p. 1116-20. 
82. Niederkorn, J.Y., Enucleation in consort with immunologic impairment promotes 
metastasis of intraocular melanomas in mice. Invest Ophthalmol Vis Sci, 1984. 25(9): 
p. 1080-6. 
83. Knisely, T.L. and J.Y. Niederkorn, Immunologic evaluation of spontaneous regression 
of an intraocular murine melanoma. Invest Ophthalmol Vis Sci, 1990. 31(2): p. 247-
57. 
84. Grossniklaus, H.E., B.C. Barron, and M.W. Wilson, Murine model of anterior and 
posterior ocular melanoma. Curr Eye Res, 1995. 14(5): p. 399-404. 
85. Ly, L.V., et al., In aged mice, outgrowth of intraocular melanoma depends on 
proangiogenic M2-type macrophages. J Immunol, 2010. 185(6): p. 3481-8. 
86. de Lange, J., et al., Synergistic growth inhibition based on small-molecule p53 
activation as treatment for intraocular melanoma. Oncogene, 2012. 31(9): p. 1105-
16. 
87. Diaz, C.E., et al., B16LS9 melanoma cells spread to the liver from the murine ocular 
posterior compartment (PC). Curr Eye Res, 1999. 18(2): p. 125-9. 
88. Yang, H. and H.E. Grossniklaus, Constitutive overexpression of pigment epithelium-
derived factor inhibition of ocular melanoma growth and metastasis. Invest 
Ophthalmol Vis Sci, 2010. 51(1): p. 28-34. 
121 
 
89. Zhang, Q., et al., In vivo high-frequency, contrast-enhanced ultrasonography of uveal 
melanoma in mice: imaging features and histopathologic correlations. Invest 
Ophthalmol Vis Sci, 2011. 52(5): p. 2662-8. 
90. Yang, W., et al., NKT cell exacerbation of liver metastases arising from melanomas 
transplanted into either the eyes or spleens of mice. Invest Ophthalmol Vis Sci, 2011. 
52(6): p. 3094-102. 
91. Niederkorn, J.Y., et al., Effect of anti-ganglioside antibodies on the metastatic spread 
of intraocular melanomas in a nude mouse model of human uveal melanoma. Curr 
Eye Res, 1993. 12(4): p. 347-58. 
92. Ma, D., et al., Association between NM23-H1 gene expression and metastasis of 
human uveal melanoma in an animal model. Invest Ophthalmol Vis Sci, 1996. 37(11): 
p. 2293-301. 
93. Ma, D., et al., Inhibition of metastasis of intraocular melanomas by adenovirus-
mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an 
athymic mouse model. Blood, 1997. 90(7): p. 2738-46. 
94. Ma, D. and J.Y. Niederkorn, Role of epidermal growth factor receptor in the 
metastasis of intraocular melanomas. Invest Ophthalmol Vis Sci, 1998. 39(7): p. 
1067-75. 
95. van Ginkel, P.R., et al., Resveratrol inhibits uveal melanoma tumor growth via early 
mitochondrial dysfunction. Invest Ophthalmol Vis Sci, 2008. 49(4): p. 1299-306. 
96. Triozzi, P.L., W. Aldrich, and A. Singh, Effects of interleukin-1 receptor antagonist on 
tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci, 2011. 
52(8): p. 5529-35. 
97. Surriga, O., et al., Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic 
uveal melanoma model. Mol Cancer Ther, 2013. 12(12): p. 2817-26. 
98. Heegaard, S., M. Spang-Thomsen, and J.U. Prause, Establishment and 
characterization of human uveal malignant melanoma xenografts in nude mice. 
Melanoma Res, 2003. 13(3): p. 247-51. 
99. Garber, K., From human to mouse and back: 'tumorgraft' models surge in popularity, 
in J Natl Cancer Inst. 2009: United States. p. 6-8. 
100. Decaudin, D., Primary human tumor xenografted models ('tumorgrafts') for good 
management of patients with cancer. Anticancer Drugs, 2011. 22(9): p. 827-41. 
101. Nemati, F., et al., Establishment and characterization of a panel of human uveal 
melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer 
Res, 2010. 16(8): p. 2352-62. 
102. Amirouchene-Angelozzi, N., et al., Establishment of novel cell lines recapitulating the 
genetic landscape of uveal melanoma and preclinical validation of mTOR as a 
therapeutic target. Mol Oncol, 2014. 8(8): p. 1508-20. 
103. Griewank, K.G., et al., Genetic and molecular characterization of uveal melanoma cell 
lines. Pigment Cell Melanoma Res, 2012. 25(2): p. 182-7. 
104. van der Ent, W., et al., Embryonic Zebrafish: Different Phenotypes after Injection of 
Human Uveal Melanoma Cells. Ocul Oncol Pathol, 2015. 1(3): p. 170-81. 
105. Kim, T.H., et al., The delivery of doxorubicin to 3-D multicellular spheroids and tumors 
in a murine xenograft model using tumor-penetrating triblock polymeric micelles. 
Biomaterials, 2010. 31(28): p. 7386-97. 
106. Vinci, M., et al., Advances in establishment and analysis of three-dimensional tumor 
spheroid-based functional assays for target validation and drug evaluation. BMC Biol, 
2012. 10: p. 29. 
107. Sutherland, R.M., J.A. McCredie, and W.R. Inch, Growth of multicell spheroids in 
tissue culture as a model of nodular carcinomas. J Natl Cancer Inst, 1971. 46(1): p. 
113-20. 
122 
 
108. Achilli, T.M., J. Meyer, and J.R. Morgan, Advances in the formation, use and 
understanding of multi-cellular spheroids. Expert Opin Biol Ther, 2012. 12(10): p. 
1347-60. 
109. Frith, J.E., B. Thomson, and P.G. Genever, Dynamic three-dimensional culture 
methods enhance mesenchymal stem cell properties and increase therapeutic 
potential. Tissue Eng Part C Methods, 2010. 16(4): p. 735-49. 
110. Desroches, B.R., et al., Functional scaffold-free 3-D cardiac microtissues: a novel 
model for the investigation of heart cells. Am J Physiol Heart Circ Physiol, 2012. 
302(10): p. H2031-42. 
111. Ivascu, A. and M. Kubbies, Diversity of cell-mediated adhesions in breast cancer 
spheroids. Int J Oncol, 2007. 31(6): p. 1403-13. 
112. Landry, J., et al., Spheroidal aggregate culture of rat liver cells: histotypic 
reorganization, biomatrix deposition, and maintenance of functional activities. J Cell 
Biol, 1985. 101(3): p. 914-23. 
113. Kelm, J.M., et al., Method for generation of homogeneous multicellular tumor 
spheroids applicable to a wide variety of cell types. Biotechnol Bioeng, 2003. 83(2): 
p. 173-80. 
114. Tung, Y.C., et al., High-throughput 3D spheroid culture and drug testing using a 384 
hanging drop array. Analyst, 2011. 136(3): p. 473-8. 
115. Angi, M., M. Versluis, and H. Kalirai, Culturing Uveal Melanoma Cells. Ocul Oncol 
Pathol, 2015. 1(3): p. 126-32. 
116. Verbik, D.J., et al., Melanomas that develop within the eye inhibit lymphocyte 
proliferation. Int J Cancer, 1997. 73(4): p. 470-8. 
117. Lake, S.L., et al., Comparison of formalin-fixed and snap-frozen samples analyzed by 
multiplex ligation-dependent probe amplification for prognostic testing in uveal 
melanoma. Invest Ophthalmol Vis Sci, 2012. 53(6): p. 2647-52. 
118. Kaliki, S., C.L. Shields, and J.A. Shields, Uveal melanoma: estimating prognosis. Indian 
J Ophthalmol, 2015. 63(2): p. 93-102. 
119. LaBarbera, D.V., B.G. Reid, and B.H. Yoo, The multicellular tumor spheroid model for 
high-throughput cancer drug discovery. Expert Opin Drug Discov, 2012. 7(9): p. 819-
30. 
120. Nyga, A., U. Cheema, and M. Loizidou, 3D tumour models: novel in vitro approaches 
to cancer studies. J Cell Commun Signal, 2011. 5(3): p. 239-48. 
121. Holliday, D.L., et al., Novel multicellular organotypic models of normal and malignant 
breast: tools for dissecting the role of the microenvironment in breast cancer 
progression. Breast Cancer Res, 2009. 11(1): p. R3. 
122. Kaur, P., et al., Human breast cancer histoid: an in vitro 3-dimensional co-culture 
model that mimics breast cancer tissue. J Histochem Cytochem, 2011. 59(12): p. 
1087-100. 
123. Abu-Absi, S.F., et al., Structural polarity and functional bile canaliculi in rat 
hepatocyte spheroids. Exp Cell Res, 2002. 274(1): p. 56-67. 
124. Riccalton-Banks, L., et al., Long-term culture of functional liver tissue: three-
dimensional coculture of primary hepatocytes and stellate cells. Tissue Eng, 2003. 
9(3): p. 401-10. 
125. Ohmori, T., et al., Blockade of tumor cell transforming growth factor-betas enhances 
cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic 
chemotherapy. Exp Cell Res, 1998. 245(2): p. 350-9. 
126. Duval, M.M., Atlas D'Embryologie 1889: Kessinger Publishing. 
127. Hamburger, V. and H.L. Hamilton, A series of normal stages in the development of 
the chick embryo. 1951. Dev Dyn, 1992. 195(4): p. 231-72. 
128. PA, R., A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM 
THE TUMOR CELLS. Journal of Experimental Medicine, 1911. 13: p. 397-411. 
123 
 
129. P, R., M. JB, and T. WH, The role of injury in the production of a chicken sarcoma by a 
filterable agent. JAMA, 1912. 59: p. 1793–1794. 
130. Murphy, J.B., FACTORS OF RESISTANCE TO HETEROPLASTIC TISSUE-GRAFTING : 
STUDIES IN TISSUE SPECIFICITY. III. J Exp Med, 1914. 19(5): p. 513-22. 
131. Murphy, J.B., STUDIES IN TISSUE SPECIFICITY : II. THE ULTIMATE FATE OF 
MAMMALIAN TISSUE IMPLANTED IN THE CHICK EMBRYO. J Exp Med, 1914. 19(2): p. 
181-6. 
132. Ribatti, D., The chick embryo chorioallantoic membrane as a model for tumor biology. 
Exp Cell Res, 2014. 
133. Tong, Q., et al., Embryonic development and the physiological factors that coordinate 
hatching in domestic chickens. Poult Sci, 2013. 92(3): p. 620-8. 
134. Wong, G.K. and M.J. Cavey, Development of the liver in the chicken embryo. I. Hepatic 
cords and sinusoids. Anat Rec, 1992. 234(4): p. 555-67. 
135. Bellairs and Osmond, Atlas of Chick Development, 3rd Edition. 2014: Academic Press. 
136. AL, R., The Avian Embryo. 1960. 
137. Weber, W.T. and R. Mausner, Migration patterns of avian embryonic bone marrow 
cells and their differentiation to functional T and B cells. Adv Exp Med Biol, 1977. 88: 
p. 47-59. 
138. Lokman, N.A., et al., Chick Chorioallantoic Membrane (CAM) Assay as an In Vivo 
Model to Study the Effect of Newly Identified Molecules on Ovarian Cancer Invasion 
and Metastasis. Int J Mol Sci, 2012. 13(8): p. 9959-70. 
139. Hagedorn, M., et al., Accessing key steps of human tumor progression in vivo by using 
an avian embryo model. Proc Natl Acad Sci U S A, 2005. 102(5): p. 1643-8. 
140. Subauste, M.C., et al., Evaluation of metastatic and angiogenic potentials of human 
colon carcinoma cells in chick embryo model systems. Clin Exp Metastasis, 2009. 
26(8): p. 1033-47. 
141. Conn, E.M., et al., Comparative analysis of metastasis variants derived from human 
prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and 
uPA-mediated invasion. Am J Pathol, 2009. 175(4): p. 1638-52. 
142. Deryugina, E.I., et al., Unexpected effect of matrix metalloproteinase down-
regulation on vascular intravasation and metastasis of human fibrosarcoma cells 
selected in vivo for high rates of dissemination. Cancer Res, 2005. 65(23): p. 10959-
69. 
143. Xiao, X., et al., Chick Chorioallantoic Membrane Assay: A 3D Animal Model for Study 
of Human Nasopharyngeal Carcinoma. PLoS One, 2015. 10(6): p. e0130935. 
144. Chambers, A.F., R. Shafir, and V. Ling, A model system for studying metastasis using 
the embryonic chick. Cancer Res, 1982. 42(10): p. 4018-25. 
145. Busch, C., J. Krochmann, and U. Drews, The chick embryo as an experimental system 
for melanoma cell invasion. PLoS One, 2013. 8(1): p. e53970. 
146. Koop, S., et al., Fate of melanoma cells entering the microcirculation: over 80% 
survive and extravasate. Cancer Res, 1995. 55(12): p. 2520-3. 
147. Taizi, M., et al., A novel and rapid in vivo system for testing therapeutics on human 
leukemias. Exp Hematol, 2006. 34(12): p. 1698-708. 
148. Shioda, T., et al., Early events of metastasis in the microcirculation involve changes in 
gene expression of cancer cells. Tracking mRNA levels of metastasizing cancer cells in 
the chick embryo chorioallantoic membrane. Am J Pathol, 1997. 150(6): p. 2099-112. 
149. Bobek, V., et al., Development of a green fluorescent protein metastatic-cancer chick-
embryo drug-screen model. Clin Exp Metastasis, 2004. 21(4): p. 347-52. 
150. Luyten, G.P., et al., A chicken embryo model to study the growth of human uveal 
melanoma. Biochem Biophys Res Commun, 1993. 192(1): p. 22-9. 
151. Berube, M., et al., MMP-2 expression in uveal melanoma: differential activation 
status dictated by the cellular environment. Mol Vis, 2005. 11: p. 1101-11. 
124 
 
152. Laurent, C., et al., High PTP4A3 phosphatase expression correlates with metastatic 
risk in uveal melanoma patients. Cancer Res, 2011. 71(3): p. 666-74. 
153. Falini, B., et al., Evolutionary conservation in various mammalian species of the 
human proliferation-associated epitope recognized by the Ki-67 monoclonal 
antibody. J Histochem Cytochem, 1989. 37(10): p. 1471-8. 
154. Balke, M., et al., Morphologic characterization of osteosarcoma growth on the chick 
chorioallantoic membrane. BMC Res Notes, 2010. 3: p. 58. 
155. Stetler-Stevenson, W.G., S. Aznavoorian, and L.A. Liotta, Tumor cell interactions with 
the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol, 1993. 9: 
p. 541-73. 
156. Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003. 3(10): p. 
721-32. 
157. Herrmann, A., et al., Cellular memory of hypoxia elicits neuroblastoma metastasis 
and enables invasion by non-aggressive neighbouring cells. Oncogenesis, 2015. 4: p. 
e138. 
158. Bilzer, M., F. Roggel, and A.L. Gerbes, Role of Kupffer cells in host defense and liver 
disease. Liver Int, 2006. 26(10): p. 1175-86. 
159. Borthwick, N.J., et al., The biology of micrometastases from uveal melanoma. J Clin 
Pathol, 2011. 64(8): p. 666-71. 
160. MacDonald, I.C., et al., Intravital videomicroscopy of the chorioallantoic 
microcirculation: a model system for studying metastasis. Microvasc Res, 1992. 
44(2): p. 185-99. 
161. Morris, V.L., et al., Mammary carcinoma cell lines of high and low metastatic 
potential differ not in extravasation but in subsequent migration and growth. Clin Exp 
Metastasis, 1994. 12(6): p. 357-67. 
162. Gomez, D., et al., The Liverpool uveal melanoma liver metastases pathway: outcome 
following liver resection. J Surg Oncol, 2014. 109(6): p. 542-7. 
163. L, D., et al., andomised study on adjuvant therapy by DTIC in choroidal melanoma. 
Ophtalmologie, 1998. 12: p. 168–173. 
164. Voelter, V., et al., Adjuvant intra-arterial hepatic fotemustine for high-risk uveal 
melanoma patients. Melanoma Res, 2008. 18(3): p. 220-4. 
165. Lane, A.M., et al., Adjuvant interferon therapy for patients with uveal melanoma at 
high risk of metastasis. Ophthalmology, 2009. 116(11): p. 2206-12. 
166. Davies, H., et al., Mutations of the BRAF gene in human cancer. Nature, 2002. 
417(6892): p. 949-54. 
167. Korn, E.L., et al., Meta-analysis of phase II cooperative group trials in metastatic stage 
IV melanoma to determine progression-free and overall survival benchmarks for 
future phase II trials. J Clin Oncol, 2008. 26(4): p. 527-34. 
168. Krishna, Y., et al., Genetic findings in treatment-naive and proton-beam-radiated iris 
melanomas. Br J Ophthalmol, 2016. 
169. Van Raamsdonk, C.D., et al., Mutations in GNA11 in uveal melanoma. N Engl J Med, 
2010. 363(23): p. 2191-9. 
170. Griner, E.M. and M.G. Kazanietz, Protein kinase C and other diacylglycerol effectors 
in cancer. Nat Rev Cancer, 2007. 7(4): p. 281-94. 
171. Shoushtari, A.N. and R.D. Carvajal, GNAQ and GNA11 mutations in uveal melanoma. 
Melanoma Res, 2014. 24(6): p. 525-34. 
172. Carvajal, R.D., et al., Study design and rationale for a randomised, placebo-controlled, 
double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in 
combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). 
BMC Cancer, 2015. 15: p. 467. 
173. JJ, S., et al., Sunitinib versus dacarbazine as first-line treatment in patients with 
metastatic uveal melanoma. J Clin Oncol, 2013. 
125 
 
174. PD, N., et al., A Cancer Research UK two-stage multicenter phase II study of imatinib 
in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM). J 
Clin Oncol, 2013. 
175. Chen, X., et al., Combined PKC and MEK inhibition in uveal melanoma with GNAQ and 
GNA11 mutations. Oncogene, 2014. 33(39): p. 4724-34. 
176. Musi, E., et al., The phosphoinositide 3-kinase alpha selective inhibitor BYL719 
enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant 
uveal melanoma cells. Mol Cancer Ther, 2014. 13(5): p. 1044-53. 
177. Garcia, P.L., et al., The BET bromodomain inhibitor JQ1 suppresses growth of 
pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene, 
2016. 35(7): p. 833-45. 
178. Delmore, J.E., et al., BET bromodomain inhibition as a therapeutic strategy to target 
c-Myc. Cell, 2011. 146(6): p. 904-17. 
179. Bandopadhayay, P., et al., BET bromodomain inhibition of MYC-amplified 
medulloblastoma. Clin Cancer Res, 2014. 20(4): p. 912-25. 
180. Lee, S., et al., Bromodomain and extraterminal inhibition blocks tumor progression 
and promotes differentiation in neuroblastoma. Surgery, 2015. 158(3): p. 819-26. 
181. Cheng, Z., et al., Inhibition of BET bromodomain targets genetically diverse 
glioblastoma. Clin Cancer Res, 2013. 19(7): p. 1748-59. 
182. Segura, M.F., et al., BRD4 sustains melanoma proliferation and represents a new 
target for epigenetic therapy. Cancer Res, 2013. 73(20): p. 6264-76. 
183. Filippakopoulos, P., et al., Selective inhibition of BET bromodomains. Nature, 2010. 
468(7327): p. 1067-73. 
184. Shao, Q., et al., BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor 
growth in vivo. Cancer Res, 2014. 74(23): p. 7090-102. 
185. Lake, S.L., et al., Single nucleotide polymorphism array analysis of uveal melanomas 
reveals that amplification of CNKSR3 is correlated with improved patient survival. Am 
J Pathol, 2013. 182(3): p. 678-87. 
186. Parrella, P., et al., Detection of c-myc amplification in uveal melanoma by fluorescent 
in situ hybridization. Invest Ophthalmol Vis Sci, 2001. 42(8): p. 1679-84. 
187. Ambrosini, G., et al., BRD4-targeted therapy induces Myc-independent cytotoxicity in 
Gnaq/11-mutatant uveal melanoma cells. Oncotarget, 2015. 6(32): p. 33397-409. 
188. Sos, M.L., et al., A framework for identification of actionable cancer genome 
dependencies in small cell lung cancer. Proc Natl Acad Sci U S A, 2012. 109(42): p. 
17034-9. 
189. Durlacher, C.T., et al., An update on the pharmacokinetics and pharmacodynamics of 
alisertib, a selective Aurora kinase A inhibitor. Clin Exp Pharmacol Physiol, 2016. 
43(6): p. 585-601. 
190. Gonzalez-Loyola, A., et al., Aurora B Overexpression Causes Aneuploidy and p21Cip1 
Repression during Tumor Development. Mol Cell Biol, 2015. 35(20): p. 3566-78. 
191. Pujade-Lauraine, E., et al., Volasertib Versus Chemotherapy in Platinum-Resistant or 
-Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs 
Nationaux pour l'Etude des Cancers de l'Ovaire Study. J Clin Oncol, 2016. 34(7): p. 
706-13. 
192. Ciceri, P., et al., Dual kinase-bromodomain inhibitors for rationally designed 
polypharmacology. Nat Chem Biol, 2014. 10(4): p. 305-12. 
193. Hoffman, B. and D.A. Liebermann, Apoptotic signaling by c-MYC. Oncogene, 2008. 
27(50): p. 6462-72. 
194. Baldin, V., et al., Cyclin D1 is a nuclear protein required for cell cycle progression in 
G1. Genes Dev, 1993. 7(5): p. 812-21. 
195. Blom, D.J., et al., Inverse correlation between expression of HLA-B and c-myc in uveal 
melanoma. J Pathol, 1997. 181(1): p. 75-9. 
126 
 
196. Mouriaux, F., et al., Differential expression of G1 cyclins and cyclin-dependent kinase 
inhibitors in normal and transformed melanocytes. Invest Ophthalmol Vis Sci, 1998. 
39(6): p. 876-84. 
197. Coupland, S.E., et al., The prognostic value of cyclin D1, p53, and MDM2 protein 
expression in uveal melanoma. J Pathol, 2000. 191(2): p. 120-6. 
198. Boi, M., et al., The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic 
Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clin 
Cancer Res, 2015. 21(7): p. 1628-38. 
199. Kasai, F., et al., Changes of heterogeneous cell populations in the Ishikawa cell line 
during long-term culture: Proposal for an in vitro clonal evolution model of tumor 
cells. Genomics, 2016. 107(6): p. 259-66. 
200. Broker, L.E., F.A. Kruyt, and G. Giaccone, Cell death independent of caspases: a 
review. Clin Cancer Res, 2005. 11(9): p. 3155-62. 
127 
 
 
Appendices 
 
Appendix 1. Representative Immunohistochemistry staining of S093-15 case plated at 8000 cells per well. A. H&E Cross section of enucleated patient eye 
followed by higher power of tumour cells within patient eye and tumour cells cultured in 2D. B. H&E and Ki67 staining of tumour cells cultured in 3D at day 3, 6 
and 9. C. MelanA, BAP1 and CD68 staining of tumour cells cultured in 3D at day 3. 
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Appendix 2. Representative Immunohistochemistry staining of S119-15 case plated at 8000 cells per well. A. H&E Cross section of enucleated patient eye 
followed by higher power of tumour cells within patient eye and tumour cells cultured in 2D. B. H&E and Ki67 staining of tumour cells cultured in 3D at day 9 . 
C. MelanA, BAP1 and CD68 staining of tumour cells cultured in 3D at day 9. 
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Appendix 3. Representative Immunohistochemistry staining of S084-15 case plated at 8000 cells per well. A. H&E Cross section of enucleated patient eye 
followed by higher power of tumour cells within patient eye. B. H&E and Ki67 staining of tumour cells cultured in 3D at day 6 and 9. C. MelanA, BAP1 and CD68 
staining of tumour cells cultured in 3D at day 9. 
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Appendix 4. Representative Immunohistochemistry staining of S121-15 case plated at 8000 and 16000 cells per well. A. H&E Cross section of enucleated 
patient eye followed by higher power of tumour cells within patient eye. B. H&E and Ki67 staining of tumour cells cultured in 3D at day 9. C. MelanA, BAP1 
and CD68 staining of tumour cells cultured in 3D at day 9. 
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Appendix 5. Representative Immunohistochemistry staining of S125-15 case plated at 4000 and 8000 cells per well. A. H&E Cross section of enucleated 
patient eye followed by higher power of tumour cells within patient eye. B. H&E and Ki67 staining of tumour cells cultured in 3D at day 9. C. MelanA, BAP1 and 
CD68 staining of tumour cells cultured in 3D at day 9. 
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Appendix 6. Representative Immunohistochemistry staining of S104-15 case plated at 8000 cells per well. Since this case was an endoresection cross section 
of enucleated patient eye was not possible A. H&E and Ki67 staining of tumour cells cultured in 3D at day 3, 6 and 9. B. MelanA, BAP1 and CD68 staining of 
tumour cells cultured in 3D at day 9 
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Appendix 7. Success rate of UM tumour nodule formation of GFP-labelled cell lines at E14, 
7 days following CAM laceration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92.1 
Experiment Number of surviving embryos Nodule formation 
1 3 1 
2 4 4 
3 2 1 
4 5 3 
5 3 2 
Total 17 11 
OMM1 
Experiment Number of surviving embryos Nodule formation 
1 2 1 
2 2 2 
3 2 2 
Total 6 5 
OMM2.3 
Experiment Number of surviving embryos Nodule formation 
1 4 0 
2 4 0 
3 5 0 
Total 13 0 
MEL270 
Experiment Number of surviving embryos Nodule formation 
1 5 0 
2 4 0 
3 5 0 
Total 14 0 
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Appendix 8. PolyAcrylamide Gel, membrane probing and development 
Acrylamide gels (10% Running/Resolving and 5% Stacking gels) were prepared for a 
Bio-Rad minigel apparatus (Bio-Rad laboratories Ltd).  4 ml resolving gel buffer 
(Geneflow, Lichfield, UK) was mixed with 5.3 ml acrylamide solution (19:1 
Acrylamide/Bisacrylamide, Geneflow) and 6.7 ml H2O. 75 µl of 10% ammonium 
persulphate (APS) (Sigma-Aldrich, UK) and 15 µl of tetramethylethylenediamine 
(TEMED) (Sigma-Aldrich, UK) were added to initiate polymerisation and left for 30 
minutes at room temperature. This solution was sufficient to prepare 2 X 1.5 mm 
PAGE gels. A 5% polyacrylamide stacking gel was prepared by mixing 1.5 ml stacking 
gel buffer (Geneflow) with 1 ml acrylamide solution and 3.5 ml H2O, 10% APS and 
TEMED were then added followed immediately by inserting a 10 or 15 well comb to 
create wells in the gels. The combs were gently removed once the stacking gel had 
set; generally after 15 minutes at room temperature. The electrophoresis tank was 
filled with 1X running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS pH=8.3). 10 µg 
of total protein was loaded per lane of gel.  The Full-Range Rainbow Molecular Weight 
Marker (GE Healthcare Life Sciences, UK) was also loaded for sizing. Gels were run 
at 35 V per gel constant voltage for 1 hour. 
The separated proteins were subsequently transferred to polyvinylidene difluoride 
(PVDF) membranes (0.45 µm pore size, Roche Diagnostic Limited, UK). The 
membranes were briefly dipped in methanol followed by cold transfer buffer (25 mM 
Tris, 190 mM glycine, 0.1% SDS pH=8.3). A transfer sandwich was prepared and 
placed in the apparatus with cold transfer buffer. An electrical current of 400 mA 
(constant current) was applied for 1 hour at 4°C. 
Membranes were blocked with the blocking buffer (5% milk in TBS-T (150 mM NaCl, 
25 mM Tris pH 7.5, 0.1% Tween 20)) for an hour to reduce non-specific binding 
between the membranes and antibodies. The membranes were then probed with the 
primary antibodies, as detailed in Table 4.2, diluted with blocking buffer overnight at 
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4 ºC with gentle agitation. Membranes were then washed with TBS-T four times and 
incubated with the appropriate secondary antibody (Table 4.3). After a final wash with 
TBST, membranes were developed with Immobilon™ Western Chemiluminescent 
HRP substrate (MerckMillipore, Watford, UK), and imaged using an LAS-1000 imager 
(Fujifilm, Japan). Equal protein loading was confirmed by probing the blots with anti 
β-Actin or Histone H3 antibodies (Table 4.3).  
 
